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Background and aim: Inflammatory bowel disease (IBD) is an increasingly prevalent 
chronic disease, frequently with an early age of onset and no cure. It is important to 
ascertain which treatments are effective and cost-effective, in order to optimise 
treatment and rationalise use of resources. One of the treatments for IBD is surgery, 
commonly restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). This 
study aimed to collect information regarding complications, outcomes, quality of life, 
disability and cost information of all IPAA patients in the Canterbury region, New 
Zealand, which will enable comparison to be made to international research and 
provide crucial information to aid treatment decisions.  
 
Method: This population study aimed to recruit all patients with IPAA performed 
between 1984 to 2013 in the Canterbury region, New Zealand, and collected 
information on demographics, indications, complications, functional outcomes, quality 
of life (QoL), disability and direct and indirect costs. Data was sourced from hospitals 
and primary care facilities. Further information was gathered from participants who 
completed the Short-Form 36 Questionnaire (SF36), the Inflammatory Bowel Disease 
Questionnaire (IBDQ), the Inflammatory Bowel Disease Disability Index (IBD-DI) and 
the Indirect Costs Questionnaire through structured interviews and online 
questionnaires. 
 
Results: In total there were 136 IPAA patients; 95 were eligible for the study after 
review (mean follow up of 11.5 years). Eighty-six completed the SF36,  81 completed 
the IBDQ, and 84 completed the IBD-DI. Twenty-four percent of patients had at least 
one early complication and 77% had at least one late complication. The average IBD-DI 
score was -1.0, which showed less disability than a cohort of UC patients on medical 
therapy in Sydney (p value = 0.04). The IBDQ and IBD-DI were highly correlated (r = 
0.84, p value <0.01). The annual average direct costs were NZD$930.42, and the 
average indirect costs in the last 12 months were NZD$3,825.38. Lower QoL and 
disability were found in those who had their position affected at work (p values <0.01) 
and those who had more than 100 days off work in the last year (p value <0.01 for QoL 
and p value = 0.012 for disability). Lower QoL and disability were associated with 





Discussion and conclusion: The IPAA patients in Canterbury, New Zealand, had a higher 
rate of late complications than the average rate observed internationally (2), likely due 
to more complete data collection from multiple sources. The quality of life in the 
Canterbury cohort was comparable to international data (4-8). Perioperative 
complications and high costs of care were associated with higher levels of disability. 
The Canterbury IPAA recipients experienced less disability than medically managed UC 
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Chapter 1. Introduction and Literature Review 
 
1.1 Ileal Pouch-Anal Anastomosis 
 
Ileal pouch-anal anastomosis (IPAA) is a surgical procedure that is carried out for ulcerative 
colitis (UC) and certain neoplastic conditions. IPAA provides continuity of the bowel and 
removes the need for a stoma, making it a desirable treatment option for many patients. 
This is particularly important as the majority of UC patients are diagnosed in their second 
and third decade of life, and many do not wish to live with a stoma for the rest of their lives. 
However, IPAA is not without possible risks and complications. Therefore, research into the 
long term IPAA complications, functional outcomes, quality of life, disability and costs will 
better inform patients, physicians and surgeons of this treatment option.    
 
As ulcerative colitis is the main indication for IPAA, this chapter will discuss the pathology 
and treatment of ulcerative colitis and other indicators for IPAA; before moving on to the 
literature review of IPAA complications, outcomes, quality of life, disability, and costs. The 
review will indicate areas that require further research, which the Canterbury IPAA study will 
aim to address.   
 
1.2 Inflammatory bowel disease 
 
Inflammatory bowel disease (IBD) is a group of inflammatory diseases with unknown 
aetiology that affects the gastro-intestinal tract, with the two main diseases being Crohn’s 
disease (CD) and ulcerative colitis (UC). UC and CD are chronic, lifelong diseases often with 
an early age of onset. The incidence and prevalence of IBD has been rising across the world 
over the last 50 years (3). The UC prevalence is 505 per 100,000 persons and the CD 
prevalence is 322 per 100,000 persons in Europe (9). Highest incidence of UC and CD have 
been reported in Northern Europe, United Kingdom and North America, with lower rates 
observed in Asia and Africa (3). The highest annual incidence of UC was 24.3 per 100,000 
person-years in Europe, 6.3 per 100,000 person-years in Asia, and 19.2 per 100,000 person-
years in North America (9). The highest annual incidence of CD was 12.7 per 100,000 person-




North America (9). Canterbury, New Zealand has the CD annual incidence rate of 16.5 per 
100,000 person-years, which is a higher annual incidence rate when compared to Europe 
and Asia, but lower than the incidence rate in North America (10).  
 
Time trend analysis in the majority of reviews and studies shows increasing incidence of IBD 
across the world (3, 9, 11-14), indicating its rise as a global disease.  The trend of increasing 
IBD incidence and prevalence, even in developing countries, indicates that there is an 
environmental link to disease pathogenesis, despite its unknown disease aetiology. One New 
Zealand study researched possible environmental risk factors by carrying out an IBD 
population case-control study, which included 653 patients with UC, 638 patient with CD, 
and 600 controls (15). Results shows a family history of IBD, cigarette smoking, high social 
class at birth and Caucasian ethnicity are significant factors associated with IBD; whilst 
having a childhood vegetable garden and having been breastfed are protective factors 
against IBD (15). The large study population and low dropout rate of 3.4% give the results of 
this study substantial statistical power. A world-wide systematic review concurs with the 
study above; that IBD family history and cigarette smoking are among one of the most 
important disease modifying factors, as well as that appendectomy is a protective factor 
Figure 1.1 - Global incidence of IBD (3) 




against UC (13). The interactions between IBD pathogenesis and environmental factors are 
complex, and no doubt there are other risk factors that are yet to be discovered, placing an 
importance on future research.  
 
1.3 Ulcerative Colitis 
 
Ulcerative colitis is a chronic disease with recurrent inflammation of the colon and rectum 
and mucosal ulcers which spreads proximally. The cause(s) of UC is unknown. However, 
research show that genetics, family history and environmental factors appear to play a role 
in disease risk (13, 15). UC has many debilitating symptoms such as: abdominal pain, 
increased bowel frequency, bowel urgency, bloody diarrhoea, anorexia, anaemia, fevers and 
weight loss. Extra-intestinal manifestations can also develop, such as: iritis, uveitis, 
seronegative arthritis, ankylosing spondylitis, sacroiliitis, erythema nodosum, pyoderma 
gangrenosum and primary sclerosing cholangitis (1). These symptoms all contribute to the 
debilitating and disabling nature of ulcerative colitis.  
 
While UC can present at any age, it typically peaks between 15 to 30 years of age and then 
again between 50 to 70 years of age (3, 11, 14). Majority of people develop UC under the 
age of 35, which is why this is a disease that affects many young people. UC has a significant 
burden on society, as it reduces patients’ quality of life and increases disability during the 
most productive years of their lives, reducing their work capacity (16-18).  
 
Fifty to eighty percent of UC patients experience a relapsing and remitting course of disease 
with varying severity, which requires treatment over prolonged periods of time (19). This has 
a large impact on health resources, as it is an expensive disease to treat with its life long 
duration, and many patients require the use of expensive biologic therapies. One study ran a 
model-based cost-utility analysis, which shows costs for anti-tumour necrosis factor therapy 
is expected to be higher than £50,000 per quality adjusted life year (QALY) gained (20). 
However, this study has its limitations, as it is a model-based analysis and not a study on real 
life patients.  
 
Due to all of the factors above, it is crucial to continue research on treatment management, 




therapies available. The Canterbury IPPA study aimed to research the complications, 
functional outcomes, quality of life (QoL), disability and costs associated with IPAA, which is 
a surgical treatment that is commonly used for UC. Therefore details of CD and other IBD 
disease were not discussed below.  
 
1.4 Medical therapy 
 
Current medical treatments are aimed at controlling the inflammatory disease process, but 
are not curative, due to unknown disease aetiology. The goal of medical therapy for UC is to 
rapidly induce a steroid-free remission while preventing and minimising disease 
complications and side effects of medications (1, 21, 22).  
 
The choice of treatment depends on a number of factors: degree of disease activity, 
distribution (proctitis, left sided or extensive colitis), course of disease, frequency of 
relapses, extra-intestinal manifestations, previous medications, side effect profiles and the 
patient´s individual wishes (22). 
 
The first-line treatment for mild to moderate UC is the use of 5-aminosalicylic acid (5ASA) 
preparations either orally or rectally. For moderate to severe disease, immunomodulators 
such as corticosteroids and azathioprine are used. For disease that is steroids dependent, 
steroid refractory, or azathioprine refractory, this is classed as refractory ulcerative colitis 
(21).  
 
For refractory colitis, it is important to ensure that first and second-line treatments are 
optimised, and intravenous corticosteroids have been trialled. After that, treatment would 
be second-line immunomodulators and biologic agents (21, 22). Second-immunomodulators 
include medications such as methotrexate, tacrolimus, and cyclosporin. Biologic agents 
include infliximab, adalimumab, as well as numerous biologic agents new to the market.  
 







Figure 1.2 - Escalating steps of UC medical therapy (23) 
(Reproduced from other sources as stated above) 
 
1.5 Surgical treatment 
 
If the disease is unresponsive to the medical therapy discussed above, or if the patient 
develops severe haemorrhage, perforation, toxic megacolon or cancer; surgical treatment 
will be the next step.  It is estimated that 20-30% of UC patients will eventually require 
surgical intervention (21, 24). The decision of whether to proceed with surgery and the 
timing of surgery, is a difficult choice that needs to be undertaken by patients and the team 
treating them on a case-by-case basis.   
 
A colectomy can cure the disease by the removal of the diseased colon and rectum; from 
here, the reconstruction options are either with an ileal pouch-anal anastomosis (IPAA) or a 
permanent stoma; the decision is dependent on multiple factors such as the extent of the 




many patients, especially those in the younger age group who do not wish to have a stoma 
for life. 
 
1.5.1 Ileal Pouch-Anal Anastomosis (IPAA) 
 
Ileal pouch anal-anastomosis, also known as an ileo-anal pouch or restorative 
proctocolectomy, is a surgically constructed internal faecal reservoir situated where the 
rectum would normally be. The reservoir is formed by folding loops of the ileum back on 
itself and stitching or stapling it together before removing the internal walls to complete the 
pouch formation. The newly constructed IPAA is then connected to the anus. An IPAA 
removes the need for a stoma and provides continuity of the bowel. For the majority of UC 
patients, this is a very desirable option.  
 
Ileal pouch-anal anastomosis was first performed in the late 1970s. The shape of an ileal 
pouch can be J, S, or W shaped, depending on the number of folds that is made from the 
terminal ileum. Over the years, techniques for IPAA have been refined. J pouches are the 
most common configuration for IPAA; they are stapled rather than hand-sewn and 
performed laparoscopically (24).  
 
In order to reduce the risk of short and long term post-op complications, this surgery is most 
commonly performed in two or three stages (24-27). The first stage is a colectomy with an 
end ileostomy to allow the body time to heal. After three to six months, patients then 
proceed to the second stage, where the IPAA is created using the terminal ileum, and joined 
to the lower rectum/anal canal. At this point, bowel contents are still diverted through an 
ileostomy in order to give the IPAA time to heal without faecal contamination. After six to 
eight weeks, patients will proceed to the third stage, which is the closure of the temporary 
ileostomy. After this, bowel contents will go through the IPAA and exit from the anus (28). 
 
Patients who are unwell at the time of the initial surgery often require the three-step 
operation. However, if condition permits, steps one and two can be combined into a single 






Figure 1.3 - Anatomy of ileal pouch-anal anastomosis (26) 
(Reproduced from other sources as stated above) 
 
1.6 Indications for surgery 
 
The mainstay of treatment for ulcerative colitis is medical therapy. However, it is estimated 
that 20–30% of patients will ultimately require surgery (21, 24, 27, 29, 30). Therefore, it is 
important to review the current indications for surgery to ensure that surgery is being 
conducted in a timely fashion.     
 
The current indications for surgical treatment can be broadly divided into two categories: 
emergency and elective (24, 25, 27, 30-32). Break down of indication percentages from a 
large IPAA study in Japan, consisting of 1000 IPAA patients are shown below in figure 1.4 and 
1.5 (25).  
 
1.6.1 Indications for emergency surgery  
• Fulminant colitis  
• Severe haemorrhage 
• Perforation 






Figure 1.4 - Indications for emergency surgery (25) 
(Data reproduced from other sources as stated above) 
 
1.6.2 Indications for elective surgery 
• Refractory to medical therapy 
• Intolerance of medical treatment 
• Frequent relapse 
• Intractable, debilitating chronic disease 
• Dysplasia or carcinoma 














Figure 1.5 - Indications for elective surgery (25) 
(Data reproduced from other sources as stated above) 
 
Large studies show that approximately 20% of operations are acute, and 80% are elective 
(24, 25, 27, 30, 31, 33), which highlights the importance of choosing and planning for 




At times, IPAA is carried out electively for non-IBD patients to reduce cancer risk in diseases 
such as familial adenomatous polyposis (FAP) and Lynch syndrome. There are no alternative 
medical treatments for this group of patients. Therefore, the only treatment is to proceed 
with a colectomy with IPAA/ileostomy for cancer excision or cancer prophylaxis. However, 
the details of this indication are outside the scope of this thesis and will not be discussed 
further.   
 
1.6.3 Timing of elective surgery 
 
The indications for surgical intervention are well established, as shown above. Failure of 
medical therapy is the most common indication for surgery (24, 25, 27, 31, 34). However, 






Refractory to medical therapy
Extra-intestinal manifestations
Dysplasia or carcinoma





subjective topic. For those patients with moderate to severe disease, it is often difficult to 
know when to cease medical therapy and to go on to elective surgery. This is a joint decision 
that is made between the patient, gastroenterologist and surgeon, based on the patient’s 
disease severity, occupation, lifestyle, morbidity, quality of life, and personal choice. 
Emphasis is placed on a full explanation of these factors so that the patient is fully involved 
in the final decision making (24).  
 
Over the years, referral patterns and indications for surgery have changed (35). Patients are 
having surgery earlier, especially if their disease is refractory to medical therapy. Many large 
and robust studies and reviews have indicated that quality of life after IPAA surgery is 




IPAA surgery, as it is for any surgery, is not without potential risks and complications. This 
section explores the complications and long-term functional outcomes for IPAA surgery. 
Complications that were experienced by IPAA patients can be split in early complications 
(<30 days post IPAA surgery) or late complications (>30 days post IPAA surgery). Common 
early complications are haemorrhage, wound infection and pelvic sepsis. Common late 
complications are strictures, pouchitis, fistula, and pouch failure. Pouchitis and pouch failure 
are late complications that I will explore further in the chapters below. 
 
A Canadian study in 2017 analysed post-operative data from 758 patients and found the 
following early complications: 17.8% had pelvic abscess(es), 17.7% had small bowel 
obstruction(s), and 14.3% had wound infection(s) (42). For late complications, this study 
found 7.3% of patients had anal stricture(s), and 3.4% had pouch fistula(s) (43). The 
strengths of this study by Zittan et al is that data was collected from a large institution, 
which has performed over 2200 IPAA, and that it was a recent study that was carried out last 
year. Limitations of this study was that it was a retrospective analysis, which may present 






The early complication rates from the above study are comparable to a 1995 study by Fazio 
et al with 1005 patients, which shows early complication rate of 27.5% (43). However, the 
late complication rate from this historic study was 50.5%, which was much higher than the 
recent study Zittan et al (44). Weaknesses from this study is that it was a retrospective 
analysis, which can present with selection and information bias. The study had data from 
patients between 1983 and 1993; this data may be out of date and no longer relevant to our 
current population of patients, due to multiple factors which may have changed over time.   
 
A large systematic review in 2016 shows early complication rate range from 9%-65%, and 
late complication rates were between 17%-55% (2). The strengths of this systematic review 
is that it was recent, systematic, and included 28 studies. Some limitations of this review is 
that due to the marked heterogeneity of the study methods, patient population, duration of 
follow up and approaches to procedures used (open vs laparoscopic), it was not possible to 
carry out a meta-analysis of the systematic review.  
 
The rate of early, late, and overall complications range widely between 20%-50% in different 
studies (2, 35, 42-49). Many of the studies that were reviewed in this literature search had 
robust study methods, large study populations and thorough systematic reviews. However, 
these studies were not without various limitations, most of which is that the data analysis 
was carried out retrospectively. It is uncertain as to why the rate of complications are so 
different between these different studies. The only conclusion that can be reached from 
current research, is that the potential complications from IPAA surgery is not to be 








Pouchitis is defined as idiopathic, non-specific acute inflammation of the ileum that has been 
used to construct the artificial reservoir that is the ileal anal pouch. Pouchitis is considered 
to be one of the most common late complications for IPAA, and it is found to be more 
common in patients with UC and CD than patients with FAP (45, 50). The rate of pouchitis in 
current research range between 12.6%-55% (2, 44, 45, 47). In a 2016 systematic review of 28 
studies, Peyrin-Biroulet found the mean incidence of pouchitis to be 29% (2). This figure was 
difficult to ascertain, due to the different study population numbers, methods, and duration 
of follow-up that was included in the 28 studies.  
 
Some may only have one or two episodes of pouchitis in their lifetime; for others, it can be 
recurrent and debilitating to the point of leading to pouch failure. A recent study by Lorenzo 
et al analysed functional outcomes and complications from 205 patients with IPAA, and 
found chronic and recurrent pouchitis in 12.6%, and pouch failure in 10.8% (47). The 
limitation of this study was its method of retrospective analysis, as well as small population 
numbers all from a single centre.  
 
Furthermore, it was shown in a study with a follow up over 20 years, that the incidence of 
pouchitis increased with time; from 40% patients reporting at least one episode over 10 
years of follow up, to 70% of patients reporting at least one episode over 20 years of follow 
Figure 1.6 - Type and frequency of post-op complications across all studies (2) 





up (45). This 2007 study had many strengths; it was a prospective study with a large study 
population of 1885 patients with IPAA, with 20 years of follow up. However, one limitation 
to note is that the data is all from a single centre, it was not a multi-centre study.  
 
In conclusion, pouchitis has been found to be one of the most common late complications of 
IPAA surgery, with a varying range of prevalence across different studies. Pouchitis can be a 





Pouch failure rate is an important piece of information that patients, physicians and 
surgeons need to be aware of. Different studies have reported different rates of pouch 
failure across the globe; ranging from the lower end at 0.9% (42), 1.6% after 10 years in 
patients older than 55 (51), to the middle ground of 5% (36, 38), and higher percentages of 
12.6% after 10 years (35). One study examined the rate of pouch failure over a long period of 
follow up, and observed pouch failure rate to increase with the passage of time. The pouch 
failure rate was 4%, 6%, and 6% after five, ten, and twenty years of follow up respectively 
(45). This was a well-designed, large prospective study with 1885 patients and 20 years of 
follow up.  
 
Pouch failure can be due to various causes. A cross-sectional study of 1554 IPAA patients in 
Canada showed failure rate of 6.8%, with 46.2% of these cases to be caused by septic 
complications (53). This is followed by the second most common cause, which is poor pouch 
functional results at 21.7% (52). One limitation of this study is its cross-sectional nature, 
where it analysed outcomes from patients who have had the IPAA for a varying length of 
time. This is likely to lead to biases and include possible confounders of the cause of 
pouchitis.   
 
One review found that pelvic abscess(es) due to anastomotic leak is a surrogate marker for 
poor wound healing (53). However, this was a small review that was not systematic, and 
quoted only a handful of small studies. A large American study of 3,234 IPAA patients carried 




sepsis after IPAA leads to worse functional outcomes and quality of life, even when it does 
not lead to pouch failure (54). This study highlighted the need for careful attention to pre-
operative and post-operative planning, in order to reduce the rate of pelvic sepsis after IPAA, 
and therefore reduce the risk of pouch failure. Limitation of this study is that it was 
retrospective and could have led to patient recall bias, particularly regarding quality of life.  
 
In contrast, a different study found having pelvic sepsis post-operatively does not impair 
functional outcomes of the IPAAs (55). One of the strengths of this Swedish study was that it 
was a prospective study, carried out over 2 years. However, it was not without some 
limitations; it was a small, single centred study which only included 100 patients with 
ulcerative colitis.   
 
A large 2016 systematic review of 28 studies and 20,801 patients shows that rate of pouch 
failure has decreased from 13% between 2002-2009, to 2% between 2010-2015 (2). The 
quoted improved rate of pouch failure could be due to several reasons; it could indicate 
improved techniques, or perhaps that patients are getting earlier surgical treatment for 
severe UC. However, these statistics must be taken with some caution, as this review 
included studies with varying methods, patient numbers, and with different duration of 
follow up. There are likely multiple factors attributing to the quoted declining rate of pouch 
failure. 
 
In conclusion, the rate of pouch failure across the world varies widely from 0.9% to 12.6% (2, 
36, 37, 39, 43, 46, 52-56).  The rate of complications reported varied widely due to different 
factors such as study method, population size and length of follow up. Further large, multi-
centre, prospective studies with long duration of follow up are required to further validate 
the current findings.  
 
1.7.1 Risk factors for complications 
 
Despite its unknown disease aetiology, studies claim certain factors have been discovered to 
increase the risk of complications for IPAA surgery. However, research in this area is full of 
conflicting results, and it can be difficult to ascertain the true risk factors leading to IPAA 




Steroids, immunomodulators and biologics 
 
There is conflicting information regarding whether the use of steroids, immunomodulators 
and biologics increase the risk of developing post-operative complications. Some studies 
report that the use of steroids and immunomodulators increase the rate of post-operative 
complications (56, 57). One of these studies (Balachandran et el) only had 54 patients; the 
other study by Kulayat et al was much larger and included 2427 patients. However, both of 
these studies were retrospective, which could lead to recall as well as selection bias.  
 
In contrast, other studies claim that there is no correlation between immunosuppressants 
and post-operative complications (58, 59). However, both of these studies were small, single 
centre and retrospective. Cyclosporin is a second-line immunomodulator used in the 
treatment of inflammatory bowel disease. One study found that intravenous cyclosporin 
doesn’t increase peri-operative complications, when compared with the use of steroids 
alone (60). However, this study was carried out in 2001, it was retrospective and only 
analysed results from 44 patients.  
 
Another possible risk factor is the use of biologics, such as infliximab. A systematic review of 
five studies with 706 patients found that Infliximab increases short term post-operative 
complication rates (61). This was a meta-analysis, however it only included 6 studies, most of 
which were small and retrospective.   
 
It is difficult to make comparisons and conclusions from these studies due to different study 
methods, retrospective nature, and varying duration of follow up.  Therefore, it remains 
unclear whether corticosteroids, immunomodulators and biologics increase the risk of post-




The use of IPAA for Crohn’s disease (CD) has long been debated, due to the nature of CD 
being able to affect any part of the gastrointestinal system. Restorative proctocolectomy, 





Multiple studies have found patients with CD to have higher complication rates and pouch 
failures (47, 49, 62). One study identified 35% of its pouch failures are patients with Crohn’s 
disease (47). This study had the strength of prospective data collection and analysis, 
compared to many other studies which are retrospective; however, it was not a large study 
and only included 205 patients. A study by Wolters et al shows CD patients has higher 
morbidity and mortality, as well as higher costs (49). This study had many strengths which 
adds to its statistical power; it was a prospective, multi-centre study spanning across nine 
countries, included 2201 patients, and had the follow up over 10 years. Therefore, CD should 




In a large study of 3407 patients with a median follow up over 10 years, the authors found 
that females were more likely to develop bowel obstructions, pouch related fistulas, faecal 
incontinence, urgency, higher daily stool frequency, and pouch failures than males (63). The 
limitations of this study was that it was single centre and retrospective. However, this risk 
factor is not found to be echoed in other large IPAA studies. Therefore, whether gender is a 
risk factor for IPAA complications still remains unclear.   
 
Delayed surgery  
 
The timing of surgery can be a complicated and difficult decision. This is dependent upon 
many factors such as disease severity, acute complications, physician recommendations and 
patient choice. One study has found delayed surgery for acute severe colitis to be a risk 
factor for IPAA complications (64). However, this was a small, retrospective and single centre 
study. The definition of ‘delayed surgery’ in itself, varies widely and is subjective. This topic 
has not been widely researched due to the different definitions of delayed surgery, which 
has led to different study methods and analysis. Therefore, it remains difficult to assess 










For many operations, increasing patient age is a risk factor for complications. However, for 
IPAA, patients over the age of 65 has been found to have the same complication rates as the 
younger patient group under the age of 65. Many studies have shown that the older patient 
group reports good functional outcomes, quality of life, and surgery satisfaction (35, 45, 47, 
48, 51, 65). Majority of these studies had many strengths, including large study population, 
prospective data collection and analysis, and long duration of follow up (20 years). A 
systematic review found the only difference is that the older patient group is more 
susceptible to dehydration post operation (65), this review included 12 recent studies. In 
conclusion, current literature has found increasing patient age is not associated with higher 
risk of post-operative complications.  
 
1.8 Functional outcomes  
 
Functional outcomes of the ileal pouch are an important aspect of life for patients after their 
IPAA operation. This is particularly relevant with the early age of onset of ulcerative colitis. 
After IPAA surgery, pouch function will have a significant and ongoing impact on quality of 
life and disability. 
 
Commonly measured functional outcome end points in IPAA studies are: defaecation 
frequency in 24 hours, nocturnal defaecation frequency, day time leakage, night time 
leakage, urgency and ability to defer defaecation. New research has shown that incomplete 
evacuation is an emerging factor that has been identified as a significant contributor to 
pouch function (66, 67).  
 
Reported mean stool frequency per 24 hours is consistent between many large international 
studies, and recorded to be between five to seven bowel motions per 24 hours (2, 42, 45, 
47-49, 65, 68-72).  
 
Daytime leakage is an important functional outcome. One Indian study reports daytime 
continence is perfect in 81% of IPAA patients. However, this study had major limitations, as 




to be more common in patients over the age of 65, by a systematic review and a large 
prospective study (45, 65). Both of these studies had significant strengths in their research 
methods, study numbers, and length of follow up. An American study found that despite the 
fact incontinence is more common in older patients (p value = 0.002 at three years), “most 
patients felt that their condition had improved or that they had no restrictions after IPAA” 
(51). Strengths of this study is that it was a prospective study, involving a sizable study 
population of 2002 IPAA patients, and followed them up with the average duration of 10.1 
years. Limitation of this study would be that it was a single centre study.   
 
A recent, large, multi-centre UK study of 2491 patients, shows that nocturnal leakage was 
8% at one year, rising to 15.4% after 20 years; urgency experienced in 5.1% at one year, 
rising to 9.1% after 15 years (48). These figures concur with other large studies and 
systematic reviews which surveyed the pouch function over a long period of follow up 
between 10 to 20 years, of which they all conclude that with the passage of time there is a 
notable increase of daytime and night time defaecation frequency, as well as nocturnal 
leakage and urgency (2, 43, 45, 47-49).  
 
Despite the increase of defaecation frequency, leakage and urgency, 80%-90% of patients 
still report good functional outcomes, quality of life and satisfaction with their IPAA, and 
would recommend the surgery to others (2, 35, 36, 42, 45-48, 65, 72). Therefore, IPAA still 
remains a good surgical option for patients with ulcerative colitis, associated with a good 
quality of life, even for patients over the age of 65.  
 
1.8.1 Sexual function 
 
Many studies do not include sexual function as a common end point. However, of the few 
studies that did include this, they found that women after IPAA experience worse sexual 
function (69, 73-75). In particular, one multi-centre study of 255 females found that 
approximately 30% of women experiences worse sexual function after IPAA surgery, 
compared to those who didn’t have surgery (70). This was a well-designed prospective case-
control study; however it was limited by its relatively small population size. Another study 
found 25.7% of men experienced retrograde ejaculation after IPAA surgery (74). However, 




showed that 36% of patients reported reduced or absent sexual activity, compared to 19% 
pre-operatively (76). This was again however, a small population study.  
 
An Italian study of 205 patients with a follow up over 20 years, found that over time, sexual 
function declined during follow up (47). However, this finding could be biased and 
multifactorial, as sexual function in the general population also declines over time. Three 
further studies found that for the majority of IPAA patients, sexual satisfaction, desire, and 
coital frequency has either been maintained at the same level or it has improved after IPAA 
surgery (77-79).  
 
It is difficult to come to a conclusion regarding sexual function and IPAA surgery, due to the 
fact most of the studies had significant limitations of study method, single centre, and a 
small study population. Therefore, it can only be suggested, that IPAA surgery may improve 
sexual function for the majority of patients, whilst worsen sexual function for others.  
  
1.9  Quality of life 
 
Quality of life (QoL), the patients’ perspective on their lives with the effects of the disease, 
has long been an important measure when evaluating the success of any treatment. This is 
especially important for inflammatory bowel disease as it is a chronic, debilitating disease 
with an early age of onset. The quality of life of a 20-year-old and how it might be for the 
rest of their lives, will impact immensely on their ability to obtain a job, work productively, 
create and maintain relationships, or have a family. Their contribution and integration with 
society rests on their quality of life.  
 
Health Related Quality of Life (HRQoL) (4), and Quality-Adjusted Life Year (QALY) (80) are 
commonly used QoL measures. In 1989, McMaster University in Canada developed a 
questionnaire specifically for IBD patients - the Inflammatory Bowel Disease Questionnaire 
(IBDQ) (81). In 2000, a UK research team adapted the IBDQ to better fit the British 







Quality of life research methods 
 
Ideally, researchers would conduct randomised controlled trials that directly compare the 
quality of life of patients on medical therapy versus surgical treatment. However, it is 
difficult to compare these two groups due to the different disease severities of patients in 
each group. As a result, studies have attempted to address this gap in research by using 
analytic models (80). One such study was conducted by Park et al; it carried out 10,000 
simulations via Markov analysis, and concludes that early colectomy in the severe disease 
group has less lifetime cost and more QALY when compared to persistent medical therapy 
(80). This study is then of course limited by the fact is was based purely on simulations. 
 
Current research in this area is limited by the lack of direct comparison between medical and 
surgical treatment. The next best method is to compare QoL before and after IPAA surgery, 
or compare IPAA with matched controls from the general population; these methods are 
widely used in IPAA research. 
 
1.9.1 Quality of life of patients with IPAA 
 
Amongst current literature, there is conflicting evidence regarding the quality of life of 
patients with an ileal pouch-anal anastomosis (4, 6, 35-37, 83-87) in comparison to the 
general population. Research of both side of the debate are laid out below.  
 
A large number of robust studies show that ileal pouch patients have a good quality of life 
that is comparable with the general population (6, 36, 37, 73, 74, 80, 83, 85, 86, 88-90). One 
such study is Heiken et al’s systematic review, which include 33 studies and 4790 patients 
with an ileal pouch. The reviewers conclude that the Health Related Quality of Life (HRQoL) 
of IPAA after 12 months post-operatively are indistinguishable from the HRQoL of the 
normal healthy population, and it improved QoL for patients compared to their QoL before 
the operation (86). However, this review does point out that it was limited by the poor 
quality of the majority of the studies it reviewed, only three studies were of what they 





These results are consistent with the findings of a large American study which shows that 
functional outcome and QoL are either good or excellent in patients with IPAA; concluding 
pouch surgery is an excellent option for IBD treatment (36). This study has many strengths, 
as it was a large, prospective study which involved 3707 pouch patients with an average 
follow up period of 87 months. The main limitation of note, is that it was an observational 
study, and did not have a control group to compare results with. Another study that 
supports this conclusion was by Heikens et al, it has sequential follow up of pouch patients 
post-operatively at 6, 12, 24 and 36 months. This study finds that QoL and health status 
increases after IPAA surgery and reaches levels comparable with those of the healthy 
reference population (37). However, this study has major limitations, as it only looked at 32 
patients with IPAA and 30 controls. The small study population would be susceptible to 
selection bias, and the results would not have good statistical power.  
 
Similarly, two other studies with matched controls reached the same conclusion (37, 85). 
One of these studies is a well-designed study with 370 patients, along with matched controls 
over a period of 15 years of follow up. Results show that pouch function positively correlates 
to QoL, and that those with good pouch function have the same QoL as the reference 
population. This study also shows that those with pouch failure have worse QoL when 
compared to both the group with good pouch function, and the reference population (85). 
This study had many strengths, with its robust method, moderate number of study 
participants with matched controls, and its long duration of follow up. The only limitation of 
note is that it was a single centre study, and its statistical power would be improved by a 
larger study population.  
 
The study by Larson et al show that patients have better QoL, body image and sexual 
function post IPAA when compared to before IPAA surgery (74). This American study 
included 289 patients with IPAA, but was majorly limited by the fact that it had a poor 
response rate of 43%. This factor in itself would lead to a self-selected population, and 
therefore presents selection bias. Another study shows that the most important factors for 
QoL are health, family, restroom access, and friends (83). This was a prospective study that 
involved 369 IPAA patients, but was limited by its method of lack of control group for 





Many studies, large and small, found that the improvement of QoL for IPAA patients is 
sustained long term (4, 6, 85, 90, 91). A study with 10 year follow up by Meyer et al found 
that greater than 85% of IPAA patients in the study has a good QoL (6).  However, this study 
has many limitations, including small study number of 36 patients and lack of detail on the 
drop-out rate and length of follow up. In van Gennep’s study, 72% were fully continent, 81% 
judged their QoL to be much better than prior to IPAA surgery, and 96% judged their 
satisfaction as “excellent” after five years post-surgery (90). This 2017 study compared 59 UC 
patients with 59 matched controls, with main limitations being small study population, and 
its limited response rate of 69%.  
 
When asked if they would recommend this surgery to others, most of the patients said yes 
(6, 36, 37, 74, 86, 89, 90, 92). This question can be a fair indication of comparison of QoL 
before and after IPAA for each patient.  
 
In contrast, fewer studies found the long term functional outcome and QoL of IPAA patients 
to be worse than the healthy reference population and other surgical groups (4, 35, 84, 93). 
One of these is a study which shows that 156 IPAA patients has a lower QoL than the general 
population (4). This study compared the 156 patients with 4152 of the general population, 
which was not matched-controlled, and had the drop-out rate of 29%. Both of these factors 
could lead to bias of results. Leowardi et al surveyed the long term functional outcome and 
QoL of patients with pouches, and finds that there is a decrease of 10.8% in QoL when 
compared to the healthy population (35). This study found the quality of life and functional 
results of patients who have had IPAA for 10 years or more are acceptable. However, QoL is 
lower than that of a healthy population (35). Strengths of this study was that it was a 
prospective cohort study of 197 patients with the median follow up period of 11.5 years. The 
limitations of this study must be noted that 29.6% did not respond to the survey, which 
could present as self-selection bias. 
 
Current literature on quality of life of patients with IPAA shows a mixed conclusion; whilst a 
large number of studies find that patients with IPAA have a good quality of life that is 
comparable to those of the general population, other studies find patients with IPAA have a 





1.9.2 Risk factors for lower quality of life 
 
Studies show there are independent risk factors that are likely to lower the quality of life of 
patients with IPAA (4, 50, 93). However, different studies report conflicting results on the 
effects of these factors on quality of life.  
 
Poor pouch function has been shown to link to lower quality of life (4, 50). Andersson et al’s 
study shows independent factors for lower quality of life are incontinence, urgency, 
nocturnal frequency and pouchitis (4). This result is echoed by a large study of 4013 patients 
in UK with mean follow up period of 7 years, which shows that the main functional risk 
factors for lower quality of life are: frequency, urgency, incontinence and the use of 
medications (anti-diarrhoeals, antibiotics) (50). The strengths of this 2010 study is that it was 
prospective, included a large study population, and followed them up for the mean period of 
7 years. Limitations would be its study method of a cohort study, which meant it didn’t have 
a control group to compare results to.  
 
One study links poor pouch function with post-operative pelvic sepsis (92). One might 
believe that pelvic sepsis may be an independent risk factor for lower quality of life. Contrary 
to what one might assume, two different studies find that pelvic sepsis does not lead to 
lower quality of life (88, 92). Selvaggi et al shows that functional outcome does not correlate 
with the level of quality of life, which is satisfactory in 95% patients across the board, 
regardless of functional outcome and pelvic sepsis (92). However, the study was limited by 
the fact it was a single centre study with small numbers, where only 88 patients completed 
the study questionnaire.  
 
One study researched patients whose pouch are salvaged despite septic complications, and 
finds that their quality of life is comparable to patient with IPAA without septic 
complications (88). Mennigan et al shows that 96% of patients with successful IPAA will 
achieve an adequate functional outcome and QoL (88).  This was a German cohort study 
including 130 IPAA patients with the follow up period of one year, and drop-out rate of 31%. 
This study presents several limitations - it had a small study population, short duration of 





A different risk factor that was reviewed, was the presence of pre-existing medical and 
psychiatric co-morbidities. One study reviewed the medical history of patients, and found 
that mental disorders, psychiatric and medical co-morbidities are risk factors for lower 
quality of life (93). This Germany study included 429 patients, however, it is likely to be 
limited by selection bias, as only 49% of the patients completed and returned the 
questionnaires.  
 
Long term studies show that the functional outcome and quality of life remain stable over a 
long period of follow up (4, 35, 41, 83, 85, 91, 94, 95), despite certain factors worsening over 
time: bodily pain, physical health, and general health perception (95).  
 
Current research of risk factors for lower quality of life show conflicting results. Some studies 
found that poor pouch function leads to lower quality of life, whilst others state that pouch 
function does not impact the level of quality of life. One area which the studies agree on, is 
that the level of quality of life remains stable over a long period of follow up.   
 
1.9.3 Comparison of quality of life with other groups 
 
IPAA versus ileostomy 
 
For various reasons – whether it be disease severity or personal preference, patients 
sometimes choose to have an ileostomy over an IPAA. Studies compare the quality of life of 
patients with an IPAA to those with an ileostomy; these studies found that patients with an 
ileostomy have a similar quality of life to those with an ileal pouch (38, 96-98). In fact, one 
study shows that the quality of life of end ileostomy and IPAA patients are similar to the 
quality of life of the general population, using the SF36 Questionnaire (96). However, this 
was a small, single centre observational study which only included 49 patients. A systematic 
review by Murphy et al mirrored the same results. However, this review state that most of 
the studies are small, and of poor quality and statistical power (97). One study went further 
than showing the same level of quality of life between ileostomy and IPAA patients; it shows 
that IPAA patients have better body image, social and sexual function than those with an 
ileostomy (38). But once again, this study is limited by small study numbers of 35 patients 





In contrast, another study compared the quality of life of patients with Koch's pouch, 
ileostomy and pelvic pouch; results show that pelvic pouch patients have the worst 
functional outcome out of the three groups (84). However, this study was limited by the 
small patient numbers of 11 Koch’s pouch, compared with 30 ileostomy and 30 IPAA.  
 
There is limited research comparing the quality of life of patients with a IPAA to those with 
an ileostomy. The existing research found that patients with an IPAA have a similar level of 
quality of life, when compared with those with an ileostomy. Most of the studies had small 
study populations and were from a single centre, therefore, what conclusion that can be 
drawn from these studies have limited statistical significance.   
 
IPAA versus Medical therapy 
 
Making the comparison of quality of life between patients with an IPAA to those on medical 
therapy is important, as it will provide crucial information to patients and doctors to enable 
them to make better informed decisions for treatment. However, this can be a very difficult 
task; considering that the most common reason for elective IPAA surgery is disease resistant 
to medical therapy. This fact alone, indicates the vastly different disease severities of the 
two groups of patients. Therefore, the comparison between the two groups can be likened 
to comparing apples with oranges.  
 
Nevertheless, one study explored the quality of life of UC patients receiving different 
therapies; it compared QoL results between patients on anti-TNF therapy, patients with an 
ileostomy and patients with an IPAA. Results show that there is no difference in the IBDQ 
score, but ileal pouch patients have a higher quality adjusted life-years (QALY) than patients 
with ileostomy and patients on anti-TNF therapy (98). This study had many strengths, it was 
a recent, large, prospective study which followed 915 patients with UC for over 2 years. 
However, it was limited by the fact that a much smaller pool of patients were actually 
compared (81 patients with IPAA and 24 patients on anti-TNF therapy). Similarly, another 
study shows that there is no difference in QoL and disability between the two groups, except 
for the fact that stool frequency is higher in the surgery group (5). However, this is a small 




remission, and surgical patients with no post-operative complications. This inclusion criteria 
can lead to selection bias, and will likely not be a true representative of the outcome in the 
whole patient group.  
 
From the studies that attempted to compare quality of life between IPAA and medical 
therapy, they conclude that there is no difference in quality of life between the two groups. 
However, these studies are limited by their small population size and study methods.  
 
Quality of life in different ethnicities 
 
Inflammatory bowel disease has been shown to mostly affect the Caucasian population (3). 
All of the studies mentioned above are based on populations in Europe or North America, 
and these results do not necessarily apply to other ethnic populations. Therefore, a few 
studies that are conducted outside of Europe and North America deserve to be mentioned 
separately. One study in India shows that quality of life improves significantly from the score 
of 0.27 pre-operatively, to 0.77 post-operatively (the score of 1 is that of a healthy, normal 
person). All patients would choose IPAA again and 94% would recommend it to others. “IPAA 
provides good functional outcome and quality of life for Indians, as well as being culturally 
appropriate” (89). However, this was a small cross-sectional study that only had 31 study 
participants. Another study from Brazil had the same result, showing that most IPAA patients 
have good long-term quality of life and functional outcome that is comparable to the general 
population (6). Once again, this study was limited by its small study population of 36 
patients.  
 
The two studies above found that despite the lower incidence and prevalence of IBD in non-
Caucasian groups; those with IBD who go on to have an IPAA, have a good quality of life and 
functional outcome that is comparable to the general population. However, both of these 
studies were of poor statistical significance, due to the limitation of small study populations.  
 
1.9.4 Quality of life conclusion 
 
Quality of life after IPAA is an important research topic due to the early age of onset of IBD. 




find long term QoL of pouch patients is comparable to the general healthy population (6, 36, 
37, 73, 74, 80, 85, 86, 88, 89), whilst other studies find long term QoL of IPAA patients to be 
worse than the general population (4, 35, 84). Large number of these studies were small and 
of a retrospective nature, whilst others had more strength in their methodology. More 
research is needed in this area to reach further conclusions.  
 
1.10  Disability 
 
Disability, as defined by WHO, is the “human experience of impaired body functions and 
structures, activity limitations, and participation restrictions in the interaction with 
environmental factors” (99). Unlike quality of life, which is subjective, disability is an 
objective measure of the effects of disease. Disability refers to an individual’s inability to 
perform a task successfully, such as if a task required more effort or time than it would 
otherwise. Disability includes problems that are experienced in different areas or health 
domains, whereas quality of life refers to how the individual feels about these limitations 
and restrictions (100).  
 
Many experts believe that disability, an objective measure of disease impact, provides more 
accurate information than a subjective measure such as quality of life. This information will 
then be used to make better informed treatment decisions. Due to the fact that IBD is a 
chronic, life-long disease with an early age of onset, it is important that disability is 
measured in this population. Researchers around the world are realising the importance of 
using disability as an outcome measure, and there are an increasing number of studies using 
disability as an endpoint.  
 
A large number of studies have attempted to assess the level of disability associated with 
IPAA and IBD. However, due to the lack of an internationally recognized tool for the 
measurement of disability, results have been found to vary widely between different studies 
conducted in different centres and countries (32, 101-103). 
 
Peyrin-Biroulet and his colleagues saw that there was a need for an internationally 
recognized tool to measure disability in the IBD population, and developed the Inflammatory 




be a comprehensive index, by using the International Classification of Functioning, Disability 
and Health (ICF) from the World Health Organization (WHO) as a guideline for inclusion of 
health domains specific to IBD. Four studies (systematic review, qualitative study, expert 
survey and cross-sectional study) were carried out in order to ascertain which ICF 
classifications are most relevant to IBD, before using these classifications to develop the IBD-
DI (100). The consensus conference included 20 IBD experts from 17 countries and led to the 
selection of 19 ICF core set categories that were used to develop the IBD-DI (101). The 
authors of this study self-identified some limitations of the development of the IBD-DI; 
samples of the qualitative studies consisted of persons from USA and France, this may have 
lead to selection bias and influenced the results of both studies (101).  
 
The IBD-DI was validated in 2013 by Leong et al, and was found to be both reproducible and 
reliable. The study recruited 166 consecutive subjects (75 CD, 41 UC, 50 controls), and found 
that the IBD-DI differentiated between CD, UC and controls (medians -7, -4, +10; p-value < 
0.001) with a score of >3.5 identifying controls with 94% sensitivity and 83% specificity. This 
study found IBD-DI correlated well to quality of life measures, changes in disease activity, 
unemployment and work absenteeism (104). Validation tests were carried out 
independently to the authors of the IBD-DI to ensure objectivity and to remove conflict of 
interest (105). IBD-DI was found to be a valid tool in measuring disability in IBD. However, 
the authors of the study did find that language simplication may make it easier for 
participants to complete. The IBD-DI is currently designed to be carried out via face-to-face 
questionnaire; self-administration would be more user friendly, but it would require further 
validation (105).  
 
1.10.1 IBD and disability 
 
Research shows that IBD patients experience a greater level of disability compare to the 
general population or other chronic illness (16, 87, 101, 105-107). A high level of disability 
has a significant economic impact, especially as IBD is a chronic illness with highest age of 
onset in the second and third decade, thus affecting the productive years of the patients’ 
lives, and therefore society as a whole. A systematic review in 2013 finds that IBD patients 




disability being worst in the young population (101). However, this review did not state its 
inclusion and exclusion criteria, nor its method of critical analysis of the studies.   
 
One study that supports this conclusion, is a case-control study conducted by Boonen et al. 
This study finds that patients with IBD are less likely to have full time employment, more 
likely to have sick leave and days off, and have chronic work disability in comparison to the 
healthy population cohort. It shows that work disability is highest in the younger and more 
highly educated group of IBD patients (107).  This study has many strengths, as it was a large 
prospective case-control study with 1395 study participants. It was however, limited by the 
poor response rate of the control group, only 48% returned the questionnaires. A cohort 
study came to similar conclusions; it found unemployment rate in IBD is higher than baseline 
population (105). This prospective cohort study in Norway included 495 participants, and 
followed them up for the duration of five years.  
 
This result was echoed in a study by Hovik et al, which reported the results of the IBSEN 
study with 518 patients over 10 years of follow up. They found that IBD patients has the 
relative risk of 1.8 (UC) and 2.0 (CD) for work disability compared with the baseline 
population, with the youngest patients having the highest relative risk (106). The strengths 
of this study is that it was a prospective study with large study population of 518 patients, 
followed up over 10 years, with the low drop-out rate of 16.5%.  
 
Another study reports that IBD patients are three times more likely to report reduced 
activity than the control group, but note that the employment rate is the same in both 
groups. This study also found that although IBD affects work quality and activities in daily 
life, IBD patients experience a similar amount of stress as the control group; in fact, IBD 
group has greater social support in place than the control group (108). This 2008 Canadian 
study was a cohort study of 388 participants with IBD, and compared the results to 2099 
participants who were ‘matched community comparisons’. One limitation of this study is 
that it only included patients who were diagnosed with IBD less than seven years ago. This 
may give a biased/skewed view of the long term results of those with IBD.  
 
Rubin et al found that when compared with other chronic illness cohorts, patients with UC 




(87). However, the survey that was used in this study was developed by the authors, and was 
not validated before its use. This study may suffer from selection bias as the cohort is of 
participants who self-selected for participation of the online surveys.   
 
Several studies find certain factors independently attribute to an increase in disability for IBD 
patients (18, 109). A large study of 942 participants by Van der Valk shows that out of the 
17% of UC patients who are chronically disabled, being older than 40 is a risk factor (110). 
This study had the strength of large study numbers, as well as the fact participants were 
followed up for two years. One could argue that its limitation could be that participants 
should be followed up for a longer period of time for a more accurate picture of the long 
term impact of illness. Naim et al looked at the association between out of pocket (OOP) 
costs and disability/morbidity of IBD patients. Higher monthly OOP costs are associated with 
higher work impairment and lower productivity; 13% of IBD patients in this study are on 
short and long term disability pension and the overall work impairment is between 10%-40% 
(109). This was an American cross-sectional study of 534 participants. It has the strength of 
large study population, but it is limited by its study method of a cross-sectional analysis, as a 
snapshot in time could present various bias and confounders.  
 
In conclusion, IBD is associated with high level of disability, work disability and 
unemployment when compared to the general population. This has a significant economic 
impact, as most IBD diagnosis is made in the second and third decade of life.  
 
1.10.2 IPAA and disability 
 
Disability as an objective measure of the impact of disease is a new concept. At the time of 
the IPAA study commencement in 2013, there were no published international studies which 
measured the level of disability associated with IPAA. The IBD-DI, a new internationally 
standardized tool to assess disability levels, has not yet been applied to patients with IPAA.  
 
The literature review did reveal a few small, historic studies which attempt to measure the 
level of disability associated with IPAA. One study in 1996 compare the cost, morbidity and 
disability between 20 patients receiving medical treatment versus 20 patients receiving 




(determined by the patient in a telephone interview) accumulated before returning to 
routine activities with an acceptable (to the patient) quality of life”. Unfortunately, this 
definition and method is flawed as it depended on what each individual patient defined as 
“acceptable quality of life”, which meant it created a subjective measure, rather than the 
objective measure which disability is meant to be (111). This was a small study that was 
qualitative rather than quantitative.  
 
Other studies defined and measured disability with factors such as the amount of sick leave 
from work, ability to return to work, and whether or not they are on the disability 
pension/benefit (46, 68). These endpoints are more fitting with work disability, rather than 
true disability. These studies highlight the fact that the lack of an internationally 
standardised definition and measuring tool for disability during this time, is hindering efforts 
in measuring disability associated with IPAA across the world.  
 
Since then, the IBD-DI was created in 2012 by Peyrin-Biroulet et al and subsequently 
validated in 2013 (100, 104). With the introduction of the IBD-DI, it is important to apply this 
to IBD and IPAA patients internationally, which will provide new information on disability 




Cost and cost-effectiveness of treatments are essential to delegation of health resources in 
any health system. This is particularly important when it comes to treating inflammatory 
bowel disease, with patients requiring ongoing treatment for the rest of their lives. IBD is a 
debilitating disease and has a large impact on patients and their ability to work, especially 
during the most productive years of life. These factors regarding IBD contribute towards its 
high economic burden on society.  
 
Costs can be divided into direct and indirect costs. Direct costs are costs associated directly 
with medical or surgical treatment at the hospital. Indirect costs are costs outside the 
hospital, and can include anything from GP visits, prescriptions, loss of work productivity, 
sick days from work, and redundancy. Due to the vast range of costs that indirect cost can 





Cost-effectiveness can be measured in Quality-Adjusted Life Year (QALY); this is a way to 
quantify the improvement of quality of life in relation to costs. Effective treatments will aid 
patients in improving their physical condition and ability to work.  
 
1.11.1 Direct Costs 
 
Research in this area is important, particularly in this current era of expensive biologic 
treatments. Biologics has been shown to reduce hospitalisations, surgeries, outpatient visits, 
improve quality of life, and reduce indirect costs, but it can contribute to significant costs 
(112). However, there are conflicting literature results when it comes to comparing direct 
cost of surgical treatments against medical treatments.  
 
A few studies show that surgical treatments are more expensive than medical treatments 
alone (113-115). One study of 540 privately insured patients show the estimated surgical 
costs from day of surgery to 180 days post-op, is USD$90,445 (114). However, this is 
information obtained solely from privately insured patients, which might not represent the 
general population. A large study of 948 patients by Odes et al, shows that surgery is the 
most expensive treatment, followed by drug-responsive hospitalisations (115). Despite the 
strength of this study due to its large study population, the study’s limitations must be noted 
as well. Much of the data from this study was acquired using Markov model analysis and 
algorithms, this naturally reduces the power of their findings.  
 
In contrast, the majority of the studies show that medical treatments are more expensive 
compared to surgical treatments (80, 98, 111, 116-118). A review by Lee at al shows that 
Infliximab is only cost-effective if you work from the point of view of USD$100,000 /QALY 
gained. This review conclude that surgical treatment is better than medical therapy when it 
comes to costs and QALY gained in the long run, despite the initial expenses encountered 
immediately post-operatively (118). However, it must be noted that this review was not a 
systematic review, which can lead to selection and information bias.   
 
One study utilised a different method of comparison, it retrospectively studied 60 patients 




method would remove many of the biases that are encountered when comparing medical 
groups with surgical groups, in particular the issue of differing disease severity in the two 
groups. The results from this study shows that the costs of the post-op period are 
USD$9,296 cheaper than the pre-operative period (116). This study is limited by its small 
study population number and retrospective nature in the methodology.  
 
Due to the difficulties of comparing the medical and surgical patient groups, some studies 
used the Markov analysis method to simulate the costs and cost-effectiveness of medical 
and surgical treatments. One study ran one-year cycles with 20 stages. It suggests that IPAA 
is more cost-effective, with more QALYs gained, than biologic treatments (117). However, 
the absolute difference between the two groups is quite small, and the results should be 
interpreted with caution. Another simulation study which ran 10,000 simulation cycles using 
Markov model analysis, shows that early colectomy has less lifetime cost, and more QALY 
gained. This study conclude that early colectomy is more cost-effective, particularly in the 
severe disease group (80). However, results from Markov model analysis remains to be 
simulations, and not data from real life research; this significantly decreases the power of 
the study’s findings.  
 
To add to the contrasting results of research on IPAA cost, some studies show that there is 
no statistically significant difference between the costs of surgical and medical therapy (111, 
119). Sher et al shows that there is no difference in cost or disability between the medical 
and surgical group. However, the surgical group has lower morbidity than the medical group. 
This study goes on to conclude that patients with severe enough disease to warrant 
hospitalisation, should be offered the opportunity to have an IPAA (111). Limitations ofthis 
study is that it is an older study that was carried out in 1996, and had the small study 
population of 40 patients.  
 
Whilst the majority of studies compared the direct costs between medical and surgical 
treatment, other studies looked into the main drivers of these costs (101, 119). One study 
shows that the driver of increased cost in the medical group is disease severity, and in the 
surgical group – pouchitis and permanent ileostomy increased costs (119). This cohort study 
followed up 120 patients for two years. A large systematic review in 2013 shows that 




limitations of this study is that this European systematic review did not state in their 
methods their search process, inclusion and exclusion criteria, nor methods of critical 
analysis.  
 
In conclusion, current research on the direct costs of surgical and medical UC treatment 
shows conflicting results. Some studies show that medical treatment is more cost-effective, 
whilst others show that surgical treatment is more cost-effective. Some studies show there 
is no difference between the two, whilst others pursued the drivers behind the costs. 
However, it must be taken into account that the disparity in cost results between different 
countries are likely due to the differing study methods and outcome measures. The only 
conclusion that can be gained is that more research is needed in this area, especially studies 
with standardised methods of evaluating costs.  
 
1.11.2 Indirect Costs 
 
Indirect costs can be difficult to measure, and even more difficult to compare between 
studies as there is no standard method on this topic. Some research in this area focus on 
costs associated with work absenteeism due to disease severity. In one study, 28.9% 
reported work absenteeism in the IBD group, compared with only 18.5% in the non-IBD 
group (16). This is a large cohort study carried out in 2003, including 187 in the IBD group, 
and 10,707 in the control group. The large study population adds to the strengths of this 
study.  
 
The average indirect costs per year (from work absenteeism) ranged from CAD$868 to 
€6,821 in different studies (16, 110, 120). A systematic review on absenteeism, presenteeism 
and loss of leisure reviewed 14 articles, and conclude that it is difficult to compare studies 
due to lack of standard method and analysis on this topic (121). This is a Canadian systematic 
review carried out in 2010, which did not include in their methodology the selection process, 
inclusion and exclusion criteria, nor method of critical analysis.  
 
Despite the difficulty in measuring indirect cost, it is a cost that should not be 
underestimated. Two studies show that indirect costs can be as high as one-third of total 




study that contained study population of 2554 patients and followed them up for two years 
(111). Its limitations are the methodology, as it was a cohort study, and not randomised 
controlled trial or case control study.  
 
In conclusion, current research shows no consensus on the indirect costs associated with 
IBD. This is due to the lack of standardised method of data collection and analysis, which 
makes comparing results nearly impossible. However, indirect costs can account for as much 
as one-third of all costs. This makes indirect costs an important issue that requires further 
research, especially the need for a standardised method of measurement.  
 
1.12 Conclusion and future research 
 
There is well-documented research on IBD background, treatment options, indications for 
IPAA surgery, and IPAA complications. However, current literature presents conflicting 
information and insufficient research regarding IPAA and quality of life, sexual function, 
disability, work disability, costs and comparisons with medical therapy.  
 
This study aims to address these unanswered questions in current research by conducting a 
population based study of IPAA patients in Canterbury with long term follow up, in order to 
determine the following: 
 
1. Surgical complications 
a. Short term complications with records from primary and tertiary care 
b. Long term complications with comprehensive follow up through the hospital, 
outpatients, and primary care records 
2. Functional outcomes 
3. Quality of life  
a. Utilising standardised international questionnaires – SF36 and IBDQ 
4. Disability 
a. Be the first to use the IBD-DI to assess the level of disability in an IPAA 
population 
b. Calculate the correlation between IBDQ and IBD-DI 




5. Comparison of quality of life and disability data to medically treated UC patients in 
Sydney 
6. Costs 
a. Direct costs 
b. Indirect costs – including costs from work absenteeism, loss of work 
productivity, alternative health resources, travel, prescriptions, tutor and 
cares 
c. Total costs 
 
The hypothesis of this study is that the Canterbury IPAA population will have comparable 
early and late complication rates, functional outcome, quality of life and costs with 
international data; and that the level of disability experienced in this population will be 
lower than a medically treated UC patient cohort in Sydney.  
 
This study will be the first to use the IBD-DI in an IPAA population, providing important 
information for comparisons of level of disability with other treatment groups. The 
information gathered from this study will be important for patients, clinicians and health 

















Chapter 2. Methods 
2.1 Population cohort 
 
This population based cohort study aimed to recruit all patients with an Ileal Pouch-Anal 
Anastomosis (IPAA) in the Canterbury region. For the purpose of this study, this included all 
patients who underwent IPAA surgery in Canterbury as well as patients who had IPAA 
surgery outside of Canterbury and later moved to the Canterbury region.  
 
After the February 2011 earthquake in Christchurch, many of those who had IPAA surgery in 
Canterbury relocated elsewhere in New Zealand. The investigators of this study decided to 
include these patients as eligible participants for the purpose of this study.  
 
2.1.1 The Canterbury region, New Zealand 
 
Canterbury is New Zealand's largest geographical region, with an area of 45,346 km² (122). 
Its borders are the Conway River to the North, the Southern Alps to the west, and the 
Waitaki River to the south. The population of the Canterbury region is 558,800 (June 2012 
estimate) (123), making it the largest region in the South Island and the second largest 
region in New Zealand by population.  
 
 




2.2 Inclusion and Exclusion criteria 
 
Inclusion criteria  
• They underwent IPAA surgery for the indications below 
• They had IPAA surgery between 1984 and 2013 
• They had ileostomy taken down prior to 1st June 2013 
• They currently live in Canterbury but had IPAA surgery elsewhere, or they underwent 
IPAA surgery in Canterbury but later moved elsewhere, or they had IPAA surgery in 
Canterbury and still live in Canterbury 
• They were over the age of 16 
• They wished to participate in the study 
 
Indications that warranted inclusion 
• Ulcerative Colitis 
• Crohn’s Disease 
• Indeterminate colitis 
• Collagenous colitis 
• Familial Adenomatous Polyposis (FAP) 
• MYH Associated Polyposis Syndrome (MAP) 
• Lynch Syndrome 
 
Exclusion criteria 
• The indication for IPAA was other than those listed in the above list 
• They did not have IPAA surgery in Canterbury and do not currently reside in 
Canterbury 
• They were deceased 
• They were less than 16 years of age 
• On review, they did not undergo IPAA surgery 









Eligible participants for this study were identified using a multi-faceted approach to ensure 
all patients who had IPAA surgery in Canterbury between 1984 and 2013 were considered.  
Participants were recruited from the following sources: 
 
Christchurch Public Hospital - All Australian classification of health interventions (ACHI) 
procedural codes associated with IPAA were identified through the Clinical Coding 
Department of Canterbury District Health Board (CDHB). All relevant ACHI procedural codes 
were applied in a search of the Christchurch Public Hospital theatre records and coding 
database to identify all IPAA procedures that were performed from 1984 to 2013.   
 
Table 2.1 - ACHI procedural codes associated with IPAA in CDHB 
Block code Clinical code Clinical code full description 
934 3205100 Total proctocolectomy with ileo-anal anastomosis 
936 3205100 Total proctocolectomy with ileo-anal anastomosis 
934 3205101 Total proctocolectomy with ileo-anal anastomosis and 
formation of temporary ileostomy 
934 3205101 Total proctocolectomy with ileo-anal anastomosis and 
formation of temp 
936 3205101 Total proctocolectomy with ileo-anal anastomosis and 
formation of temporary ileostomy 
934 3205102 Total proctocolectomy with ileorectal anastomosis 
934 3205103 Total proctocolectomy with ileorectal anastomosis and 
formation of temporary ileostomy 
934 3205103 Total proctocolectomy with ileorectal anastomosis and 
formation of temp 






Colorectal surgeons - The surgical paper records of Christchurch Public Hospital colorectal 
surgeons were searched manually for IPAA procedures that were performed during the 
study period.  
 
Canterbury private hospitals - The Christchurch private hospitals’ patient databases were 
accessed and searched for patients who underwent IPAA surgery during the study period.  
 
The Canterbury IBD clinical database (124)- Professor Richard Gearry established the 
Canterbury IBD Clinical Database in 2006; this database was accessed and searched for all 
IBD patients with an IPAA from 2006 to 2013.  
 
Referrals - Colleagues in the gastroenterology and colorectal surgery departments were 
made aware of this study and its aim to recruit all IPAA patients in Canterbury. 
Subsequently, colleagues have identified and referred eligible participants for this study.  
 
Self-referrals - Patients were able to enter the study through self-referral. Advertisements 
with details of the study and contact details of the investigators were presented in several 
locations: three different waiting rooms of Christchurch Hagley Outpatients, the waiting 
room of Christchurch Colorectal private clinic, and the Facebook page of Crohn’s and Colitis, 
New Zealand.  
 
Local support group meetings - One of the investigators of this study attended the annual 
Canterbury Crohn’s and Colitis meeting in May 2013, and gave a brief presentation about the 
study. This presentation included contact details of the investigators of this study, for those 




Consenting for participation in this study involved agreeing to complete four questionnaires 
and allowing investigators of this study to access medical and costs records for IPAA 





All eligible participants were sent an invitation letter to join the study, along with an 
information sheet, consent form, questionnaire preference form and a self-addressed return 
envelope. Two weeks after the invitation letters were posted, follow up phone calls were 
made to eligible participants who did not respond to the letter. The investigator who made 
the phone call checked with the eligible participant whether or not they had received the 
invitation letter. If the letter was received, they were asked if they would like to participate 
in the study.  
 
A number of eligible participants had relocated after the Christchurch February 2011 
earthquake and required an invitation letter to be sent to their new address. For those who 
declined to participate in the study, this was noted and they were excluded from the study.  
 
2.5 Data Collection 
 
This study collected the following information from its participants:  
• Indication for IPAA surgery 
• Long term complications and outcomes 
• Quality of life (SF36 and IBDQ questionnaire) 
• Disability (IBD-DI) 
• Direct costs 
• Indirect costs 
 
Indications, surgical outcomes and complications - Participants’ medical records were 
accessed from primary care, private and public outpatient clinics and all private and public 
inpatient episodes from the point of colectomy to the end of the study period. Demographic 
data, outcomes, details of surgical and on-going medical treatment and complications were 
collected by reviewing these records.    
 
Quality of life, disability and indirect costs - Participants were contacted and asked to 
answer the following questionnaires regarding information about their quality of life, 





• Inflammatory Bowel Disease Questionnaire (IBDQ) 
• Short Form 36 Health Survey (SF36) 
• Inflammatory Bowel Disease Disability Index (IBD-DI) 
• Indirect Costs Questionnaire 
 
Participants were given the option to complete the questionnaires as a structured interview, 
a phone interview, on paper, or online. The only exception to this was the Inflammatory 
Bowel Disease Disability Index (IBD-DI), as the IBD-DI was designed to be carried out in an 
interview and had not yet been validated for self-reporting. Therefore, the IBD-DI was 
administered in either a face-to face-interview; or a phone interview, depending on the 
participant’s preference.  
 
Online questionnaires were collected by using Question Pro, and data was entered into an 
excel database, before exporting it to SPSS for data analysis.  
 
Sydney data - The Canterbury Ileal Pouch study was fortunate in that we were able to 
collaborate with the Sydney study that was being carried out concurrently at the time. The 
Sydney data was collected by the research team under Professor Rupert Leong, whom 
collected the IBDQ score and the IBD-DI score of their participants. As both the Sydney study 
and the Canterbury study utilised identical questionnaires, we were able to compare and 
contrast the results. 
 
Indirect costs - For the purpose of this study, indirect costs refers to money that was lost 
due to associated symptoms or complications from their IPAA surgery which resulted in: 
 
• Work or school absenteeism 
• Loss of work productivity 
• Use of alternative or complementary health resources for associated symptoms 
• Travel to attend appointments or treatment 
• Carers for themselves or others in their care 
• Tutors 





This information was collected by using a questionnaire which one of the investigators of the 
study developed - the Indirect Costs Questionnaire. In the questionnaire, participants were 
asked to estimate their indirect costs associated with symptoms or complications from their 
IPAA surgery over the last 12 months. Participants were also offered the opportunity to 
nominate other costs that were not mentioned in the questionnaire. 
 
Indirect costs that were incurred through work absenteeism as a result of illness were 
calculated by the human capital method as described by Drummond et al (125). In this 
method, participants were asked the number of days they had off work as either unpaid or 
annual leave related to IPAA, which was then transferred into hours off work and multiplied 
by their gross hourly wage. For those patients not in work their indirect costs are discussed 
descriptively as monetary values.  
 
Direct costs – Annual direct cost from 2006/07 financial year to 2012/13 financial year. Data 
on long term direct costs associated with having an IPAA was collected from several sources: 
Christchurch Public Hospital, private hospitals in Canterbury, primary care, and PHARMAC. 
Details of each source is as below: 
 
Christchurch Public Hospital - The costs of hospital resources were determined through the 
Costing Department of the Canterbury District Health Board (CDHB) and the Ministry of 
Health. These costs were calculated by using DRG codes, which is a unique code assigned to 
the patient each time they visited the hospital for either inpatient or outpatient visits. A 
different code is given for each service required during each visit, and the total cost for each 
visit was calculated accordingly. The investigators of this study have obtained all the codes 
and costs accrued by the patients from the CDHB Decision Support Department and Costing 
Department from the beginning of the 2006/7 financial year. Data prior to this financial year 
was unfortunately not available in the digital system.  
 
Christchurch private hospitals - A number of the participants in the study had their IPAA, day 
procedures and outpatient clinics carried out in the private sector. Private hospitals were 





In the private system in Christchurch, surgeons and anaesthetists charge for fees 
independently of the general private hospital costs. An inflation adjusted fee estimate was 
applied to all participants who had surgery in the private sector.  
 
Christchurch primary care practices - For primary care cost, it was assumed that all patients 
were enrolled in a Primary Health Organisation (PHO). The New Zealand Government 
provides subsidies to lower the cost of general practitioner (GP) visits for eligible patients 
that are enrolled in a PHO. The cost of GP services was estimated using the average cost of 
an appointment by age as obtained from Pegasus Health PHO and the 2012 yearly capitation 
rates provided by the Government. The capitation rates took into account whether or not 
the patient had a high user health card (HUHC). 
 
Pharmaceuticals - Pharmaceutical costs that were related to symptoms and complications 
from their IPAA were calculated from the cost to the Pharmaceutical Management Agency in 
New Zealand (PHARMAC) provided by their pharmaceutical schedule. Additionally, a 4% 
mark-up was added to pharmaceutical costs plus a NZD$5.80 dispensing fee attributable to 
pharmacists. The co-payments paid by the patient were a transfer, not a cost; therefore 
these were not included.  
 
Total average cost - The average cost of all the participants’ direct and indirect costs over 
the past 12 months.  
 
2.6 Statistical analysis methods 
 
Each variable of the data was first analysed descriptively using frequencies, means, medians, 
confidence intervals, standard deviation, range of scores, skewness and kurtosis, dependent 
on whether the variable was categorical or continuous. Scatter plots and other graphs were 
then drawn to establish the relationship between variables before further data analysis. 
Correlation and comparisons were made using the following tests where appropriate: 
Pearson product-moment correlation coefficient, multiple regression analysis, Chi-square 
test, and paired T-tests. Results were considered statistically significant if p value <0.05. 




Chapter 3. Results 
 
3.1 Participant identification 
 
Eligible participants for this study were identified using a multi-faceted approach as stated in 
the methods. 
 
Christchurch Public Hospital - All relevant ACHI procedural codes were applied in a search 
through the Christchurch Public Hospital theatre records and coding database to identify all 
IPAA procedures that were performed from 1984 onwards. However, data prior to 1997 was 
not available on the system. This search yielded 98 possible eligible participants for the 
study. After application of the study criteria, 46 were excluded as they did not have an IPAA, 
and three were excluded as they were deceased.  
 
Miscoding in the Christchurch public system - The search through clinical coding records for 
IPAA patients revealed a considerable amount of miscoded data within the Christchurch 
Pubic Hospital system. Out of the 98 cases identified by ACHI procedural coding, 46 were 
incorrectly coded; which meant that only 52% of the data was correctly coded in the results 
of this search. Most of the miscoded cases were colorectal malignancies which resulted in an 
anterior resection; no IPAA were formed in these cases despite it being coded as an IPAA.  
 
Christchurch Colorectal surgeons - The Colorectal Surgery Department of Christchurch 
Public Hospital keeps a hard copy of all operation notes performed by the colorectal 
surgeons. These operation records were searched manually for IPAA surgery that was 
performed in the study period.  
 
This search yielded 31 possible eligible participants for the study; none of whom were 
excluded after application of the study criteria. 
 
Christchurch private hospitals - There are two private hospitals with operating capacity in 
Canterbury: Southern Cross Hospital and St. George’s Hospital. Managers from these two 




Christchurch private hospitals’ patient databases were accessed and searched for IPAA 
procedures that were performed. Data was only available from 2006 onwards.  
 
Seven possible participants were identified by Southern Cross Hospital, and nine possible 
participants were identified by St George’s Hospital. After application of the study criteria, 
four patients were noted to have already been identified for the study by previous search 
methods, and three patients were excluded as they either did not have IBD, or did not have 
an IPAA.  
 
Canterbury IBD clinical database - Associate Professor Richard Gearry established the 
Canterbury IBD Clinical Database (124) in 2006; this database was accessed and searched for 
all IBD patients with an IPAA. From this database, 43 possible eligible participants were 
identified. One patient was noted to have already been identified for the study by previous 
search methods.  
 
Referrals - Three possible eligible participants were identified via referral from colleagues in 
the Gastroenterology Department and Colorectal Surgery Department. None of these 
patients were excluded after application of the study criteria. 
 
Self-referrals - Five patients self-referred for the study, three were excluded upon 
application of the study criteria as they did not have an IPAA. 
 
Possible eligible patients - Through the various approaches in identification of all patients 
with IPAA in Canterbury, the final number of possible eligible participants for this study was 
136.  
 
3.2 Participant recruitment 
 
Contact rate - The 136 patients in Canterbury with IPAA were first contacted with a study 
invitation letter, then a follow up phone call. Out of the 136 patients, eight were deceased, 
four had yet to have their stoma taken down, and 29 were unable to be contacted via mail 




eligible participants, but this did not yield any results. This left us with 95 possible eligible 
participants for the study.  
 
Participation rate - Out of the 95 possible eligible participants that were able to be 
contacted for the study, 86 (91%) agreed to participate in the study, while nine declined 
participation.  
 
Completion of questionnaire and data availability - From the 86 participants in the study: 
86 completed the Short Form 36 Health Survey, 81 completed the Inflammatory Bowel 
Disease Questionnaire, 84 completed the Inflammatory Bowel Disease Disability Index, and 








Table 3.1 - Data availability 




SF36  86 (100)  
IBDQ 81 (94.2)  
IBD-DI 84 (97.7)  
Indirect Cost Questionnaire 85 (98.8)  
Clinical data 86 (100)  
Primary care data 86 (100)  
Hospital costs data 86 (100)  
All data 81 (94.2)  
 
 
3.3 Participant demographics 
 
Table 3.2 - Participant demographics 









 NZ European/Pakeha 
 Other European 
 NZ Maori 







Participant characteristics (n=86) Mean (SD)  
Age 51.1 (12.9)  
Age at surgery 40.1 (12.0)  










Out of the 86 study participants, 38 were female and 48 were male. The ethnicities of the 
study participants were split into New Zealand European/Pakeha, Other European, New 
Zealand Maori, other, or not stated. There were 72 participants that identified as New 
Zealand European/Pakeha; five participants identified as other European; two participants 
identified as New Zealand Maori; seven participants identified as other or it was not stated.  
 
The mean age of participants was 51.1 years old, with the oldest participant being 77, and 
the youngest being 18. The average age at surgery was 40.1 years old, with the youngest age 
at surgery being 16, and the oldest age at surgery being 65. The years of retrospective follow 
up range from 0 to 43 years, with the average follow up being 11.5 years. Participants’ 
average BMI was 25.9 (4.4).  
 
The indications were divided into acute or elective. Indications for acute or emergency 
surgery were: fulminant colitis, haemorrhage, perforation, toxic megacolon, or obstruction. 
Indications for elective surgery were: failure of medical therapy, dysplasia, intolerable side 
effect of medical therapy, intractable chronic disease, familial adenomatous polyposis (FAP) 
or Lynch syndrome.  
 
Participants were identified and grouped by their disease type. The type of diseases that 
were included in the study were: ulcerative colitis, Crohn’s disease, indeterminate colitis, 
familial adenomatous polyposis, FAP or other. 
 
Table 3.3 - Disease type and clinical indications 
Disease Type Frequency (Percentage)  
Ulcerative colitis 67 (79.8) 
Crohn’s disease 8 (9.5) 
Indeterminate colitis 2 (2.4) 
FAP 7 (8.3) 
Clinical Indications Frequency (Percentage) 
Failed medical therapy 55 (65.5) 
Fulminant colitis 12 (14.3) 




FAP 7 (8.3) 
Other or unknown  4 (4.8) 
 
3.4 Surgical complications 
 
Surgical complications were split into early (<30 days after IPAA surgery), or late (>30 days 
after IPAA surgery). Early complications that were identified were: haemorrhage requiring 
transfusion, wound infection, pelvic sepsis, gastrointestinal obstruction and medical 
complications. Late complications that were identified were: gastrointestinal obstruction, 
acute pouchitis, chronic pouchitis, incisional hernia, peri-anal disease (including peri-anal 
fistula, abscess, anal stenosis and strictures), pouch failure and other complications. Data on 
long term outcomes and complications of participants were determined by assessing 
medical records from hospitals and general practices.  
 
Table 3.4 – Complications 
Early complications  
(≤30 days after RP with IPAA)  
 
Frequency (Percentage)  
Haemorrhage requiring transfusion 8 (9.6) 
Wound infection 7 (8.4) 
Pelvic sepsis 7 (8.4) 
Small bowel obstruction 4 (4.8) 
Any early complications 20 (24.1) 
No early complications 63 (75.9) 
Late complications  
(>30days after RP with IPAA) 
 
Frequency (Percentage) 
Small bowel obstruction 36 (42.9) 
Pouchitis 49 (58.3) 
Abscess or fistula 26 (31.0) 
Stricture 15 (17.9) 
Pouch failure (all with stoma) 10 (11.9) 
Any late complications 65 (77.4) 





3.5 Functional outcomes 
 
Participant’s average number of bowel motion (BM) in 24 hours was 7.24 (3.29). The average 
night time BM was 1.63 (1.34). 
 
Table 3.5 - Average BM frequency 
Bowel motion frequency Mean (SD) 
Average number of BM in 24 hours 7.24 (3.29) 
Average number of BM overnight 1.63 (1.34) 
 
 
3.6 Quality of life 
 
Participants were asked to answer two questionnaires regarding their quality of life; the 
Inflammatory Bowel Disease Questionnaire (IBDQ) and Health Form 36 Health Survey (SF36). 
The higher the score, the higher the level of quality of life was experienced by participants.  
 
3.6.1 IBDQ score univariable analysis 





Difference - Mean (95% CI)  
or Report estimate (95% CI) 
 
All participants 81 170.3 (28.3) N/A N/A 
Gender     
Female 35 160.1 (29.7) (Reference)  
Male 46 178.0 (24.7) -15.8 (-28.7 to -4.6) 0.013* 
Ethnicity     
NZ European 
(Reference) 
68 172.1 (28.3) Mean square between groups = 
279.180 
F = 0.345 
0.793 
Other European 5 162.5 (15.4)  0.45 




Other 6 160.3 (36.7)  0.63 
Age     
50 or younger 39 170.4 (29.1) (Reference)  
Older than 50 42 170.1 (27.8) 0.3 (-12.1 to 13.0) 0.97 
Years since surgery     
Less than 12 38 173.6 (27.6) (Reference)  
12 or more 42 168.2 (29.2) 5.4 (-17.6 to 7.4) 0.40 
Age at surgery     
Younger than 40 37 173.9 (26.6) (Reference)  
Older than 40 44 167.2 (29.5) -9.0 (-20.0 to 4.9) 0.16 
Level of education     
<Secondary  
(Reference) 
6 166.2 (30.0) Mean square between groups = 
260.429 
F = 0.310 
0.818 
Secondary 40 170.7 (28.7)  0.66 
Tertiary 26 170.0 (29.5)  0.77 
Trades 5 182.8 (30.1)  0.39 
Employment status     
Employed 57 175.0 (23.2) (Reference)  
Not employed 23 159.2 (36.6) -15.2(-29.9 to -2.7) 0.09 
Position at work      
No 61 178.3 (23.3) (Reference)  
Yes 14 139.3 (31.0) -39.0(-53.2 to -25.0) 0.000* 
Days of leave taken     







-35.9(-56.7 to -14.7) 
 
0.000* 
Disease groups     
Crohn’s disease 
(Reference) 
8 152.4 (28.0) Mean square between groups = 
599.404 
F = 0.751 
0.561 
Ulcerative colitis 64 171.9 (25.6)  0.04* 














Not Crohn’s disease 73 172.2 (27.8)  0.053 
Indications     
Failed medical therapy 
(Reference) 
54 166.2 (27.4)  Mean square between groups = 
884.162 




12 179.9 (22.3)  0.12 
Dysplasia 6 174.3 (23.0)  0.76 
FAP prophylaxis 6 177.0 (47.4)  0.42 
Other 2 200.5 (4.9)  0.09 
Early complications     
No early complications 
(Reference) 
64 174.0 (26.1) N/A N/A 
Haemorrhage 7 167.2 (16.7)  0.84 
Small bowel 
obstruction 
4 128.0 (45.3)  0.01* 
Wound infection 7 164.7 (28.7)  0.66 
Pelvic sepsis 6 146.2 (10.1)  0.01* 
Any early 
complications 
17 156.0 (32.2)  0.03* 
Late complications     
No late complications 
(Reference) 
21 177.2 (27.2) N/A N/A 
Small bowel 
obstruction 
33 162.2 (31.6)  0.10 
Pouchitis 46 169.9 (27.3)  0.31 
Abscess or fistula 22 163.4 (29.0)  0.10 
Stricture 13 151.7 (38.7)  0.03* 
Pouch failure (all with 
stoma) 




Any late complications 60 167.8 (28.4)  0.19 
Average TOTAL Costs 
in NZD (year 2013) 
    
<$300 32 184.1 (23.9) (Reference)  
>$300 48 161.9 (27.9) -22.2 (-32.2 to -8.3) 0.001* 
Average Direct Costs in 
NZD (year 2013) 
    
<$300 53 173.4 (27.6) (Reference)  
>$300 27 165.6 (29.7) -7.8 (-7.6 to 17.3) 0.25 
Average Indirect Costs 
in NZD (year 2013) 
    
<$300 40 182.1 (24.5) (Reference)  
>$300 40 159.4 (27.7) -22.7 (-32.6 to -9.3) 0.001* 
* = p value less than 0.05 
 
Eighty-one participants completed the IBDQ, which is scored from 70 to 224. The average 
IBDQ score for this study was 170.3, with the standard deviation of 28.3. Females had a 
significantly lower IBDQ score than males in this study, as did participants whose position at 
work was affected by their bowel condition, and those who had to take more than 100 days 
off work in the past 12 months. Participants with Crohn’s disease had a significantly lower 
score than participants with ulcerative colitis. Participants who had small bowel 
obstruction(s) or pelvic sepsis(es) scored significantly lower in the IBDQ than those without 
any early complications. In terms of late complications, those who developed stricture(s) as 
a late complication scored lower than participants who did not have any late complications. 
Those who had an average total costs and average indirect costs greater than NZD$300, 
scored significantly lower in the IBDQ score compared to those who had an average total 
costs and average indirect costs less than NZD$300, respectively.   
 
3.6.2 SF36 score univariable analysis 
 
SF36 is broken down into several components and the scores range from zero to one 





Table 3.7 - SF36 components 
SF36 components Mean (SD) 
Physical functioning 83.7 (21.4) 
Social functioning 77.6 (27.6) 
Vitality 49.8 (26.3) 
Bodily pain 74.2 (22.5) 
Emotional well being 77.4 (16.9) 
General health 59.6 (26.3) 
Role limited by physical health 68.3 (41.4) 
Role limited by emotional health 77.5 (36.7) 
Physical health 71.5 (23.4) 
Mental health 70.6 (22.0) 
 
Some of these components can be accumulated into an average to represent physical health 
and mental health. Univariable analysis of these two accumulated variables are as below: 
 
3.6.2.1 SF36 score physical health 







Mean (SD)  
Univariable analysis  
Difference - Mean (95% CI) or 
Report estimate (95% CI) 
 
p value 



































Mean square between groups = 
419.415 
F = 0.761 
 
0.519 




50 or younger 






0.9 (-0.9 to 11.3) 
 
0.864 
Years since surgery 
Less than 12 













Age at surgery 
Less than 41 





























Mean square between groups = 
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Days of leave taken 

































Mean square between groups = 
491.454 
















Mean square between groups = 
141.061 






































-2.5 (-19.0 to 14.0) 
-11.8 (-30.1 to 6.5) 
-6.6 (-25.0 to 11.9) 
-24.1 (-47.5 to -0.7) 































-11.7 (-21.6 to -1.8) 
-1.2 (-11.4 to 8.9) 
-10.4 (-20.3 to -0.6) 
-18.5 (-32.5 to -4.5) 
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0.7 (0.6 to 0.8) 







IBD Disability Index 84 N/A 1.6 (1.3 to 2.0) 0.000* 
* = p value less than 0.05 
 
Eighty-six participants completed the SF36PH questionnaire, which is scored from 0 to 100. 
The average SF36PH score for this study was 71.5, with the standard deviation of 23.4. 
Females had a lower SF36PH average score than males, as did participants who were 
unemployed, had their position at work affected by their bowel condition, and those who 
had to take more than 100 days off work in the past 12 months. In terms of complications, 
participants who had pelvic sepsis(es), GI obstruction(s), peri-anal disease, pouch failure, and 
any late complications scored significantly lower in the SF36PH than those who did not have 
any late complications. Participants who had total costs and indirect costs greater than 
NZD$300 per year scored lower in SF36PH than participants who had costs that were less 
than NZD$300. SF36PH score had a linear relationship with the SF36MH, IBDQ, and the IBD-
DI. 
 
3.6.2.2 SF36 score mental health 







Mean (SD)  
Univariable analysis 
Difference - Mean (95% CI) or 
Report estimate (95% CI) 
 
p value 



































Mean square between groups 
= 208.566 
















Older than 50 44 69.3 (23.4) -2.8 (-12.5 to 6.9) 0.567 
Years since surgery 
Less than 12 













Age at surgery 
Less than 41 





























Mean square between groups 
= 231.480 
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= 685.528 

































































-11.7 (-27.0 to 3.5) 
-3.2 (-20.5 to 14.0) 
0.2 (-17.1 to 17.6) 
-23.0 (-44.9 to -1.1) 





































-11.5 (-20.8 to -2.2) 
0.6 (-8.9 to 10.2) 
-9.1 (-18.4 to 0.2) 
-9.4 (-22.9 to 4.1) 


























































>$300 43 73.3 (19.3) 5.4 (-4.2 to 15.0) 0.267 
Average Indirect 


































0.6 (0.5 to 0.7) 






84 N/A 1.6 (1.3 to 1.9) 0.000* 
* = p value less than 0.05 
 
Eighty-six participants completed the SF36MH questionnaire, which is scored from 0 to 100. 
The average SF36MH score for this study was 70.6, with the standard deviation of 22.0. 
Participants who were unemployed, had their position at work affected, or took more than 
100 days of leave had a significantly lower SF36MH score. Those who had pelvic sepsis(es) 
and GI obstruction(s) scored lower than those who did not have any early and late 
complications. Participants who had total costs and indirect costs greater than NZD$300 per 
year, scored lower in SF36MH than participants who had costs that were less than NZD$300. 




The World Health Organisation defines disability as “an impairment or problem in body 
function or structure; an activity limitation is a difficulty encountered by an individual in 
executing a task or action; while a participation restriction is a problem experienced by an 









Inflammatory Bowel Disease Disability Index (IBD-DI) 
 
Participants were asked to answer the IBD-DI, which is a questionnaire developed to 
specifically score patients’ physical disability. At the time of this study, this questionnaire has 
not yet been validated for self-reporting. Therefore, this questionnaire was carried out via 
either a face-to-face interview or phone interview.  
 
The IBD-DI score ranges from -80 to +22; the more negative the score, the worse the level of 
disability that was experienced by the participant.  
 







Difference - Mean (95% CI)  
or Report estimate (95% CI) 
p value 
All participants  84 -1.0 (9.9) N/A N/A 
Gender      




 47 0.6 (9.5) 3.6 (-0.2 to 8.3) 0.09 
Ethnicity      
NZ European 
(Reference) 
 70 -0.7 (10.0) Mean square between groups = 
21.802 
F = 0.218 
 
Other European  5 -2.4 (7.8)  0.72 
NZ Maori  2 -7.0 (19.8)  0.40 
Other  7 -1.0 (9.7)  0.95 
Age      
50 or younger  40 -0.3 (9.9) (Reference) 
 
Older than 50  44 -1.7 (10.1) -1.38 (-5.6 to 3.0) 0.53 
Years since surgery      
Less than 12  39 -0.6 (9.8) (Reference) 
 
12 or more   45 -1.4 (10.1) -0.76 (-5.0 to 3.6) 0.73 




Less than 41  40 1.3 (8.9) (Reference) 
 
41 or more  44 -3.1 (10.5) -4.44 (-8.1 to -0.3) 0.04* 
Level of education      
<Secondary 
(Reference) 
 6 -4.0 (11.5) Mean square between groups = 
80.094 
F = 0.765 
 
Secondary  39 -1.1 (10.7)  0.54 
Tertiary  27 -1.5 (9.7)  0.58 
Trades  5 5.0 (9.3)  0.19 
Employment status      
Employed  57 0.0 (8.8) (Reference) 
 
Not employed   23 -4.0 (12.5) -4.0 (-9.3 to 0.4) 0.11 
Position at work      
No  62 1.2 (8.7) (Reference) 
 
Yes  14 -12.2 (9.6) -11.0 (-18.6 to -8.5) 0.01* 
Days of leave taken      
≤100 days  74 -0.2 (9.7) (Reference)  
>100 days  7 -10.1 (9.8) -9.9 (-17.5 to -2.2) 0.012* 
Disease groups      
Crohn’s disease 
(Reference) 
 8 -8.3 (11.9) Mean square between groups = 
180.410 
F = 1.935 
 
Ulcerative colitis  67 -0.5 (8.7)  0.03* 
Indeterminate colitis  2 -9.5 (16.3)  0.90 
FAP  7 4.9 (13.6)  0.07 
Not Crohn’s disease  76 -0.2 (9.5)  0.03* 
Indications      
Failed medical 
therapy (Reference) 
 55 -3.3 (9.7) Mean square between groups = 
217.404 








Dysplasia  6 1.7 (9.7)  0.24 
FAP prophylaxis  7 4.9 (13.6)  0.05* 
Other  2 8.5 (0.7)  0.09 




 63 -0.4 (9.4) N/A N/A 
Haemorrhage  8 1.5 (7.1)  0.57 
Small bowel 
obstruction 
 4 -14.5 (19.4)  0.24 
Wound infection  7 -3.4 (11.4)  0.44 
Pelvic sepsis  7 -7.3 (8.0)  0.07 
Any early 
complications 
 20 -3.4 (11.4)  0.25 




 19 0.1 (11.1) N/A N/A 
Small bowel 
obstruction 
 36 -2.6 (9.9)  0.36 
Pouchitis  49 -0.3 (9.5)  0.88 
Abscess or fistula  26 -3.3 (9.4)  0.27 
Stricture  15 -6.1 (13.3)  0.15 
Pouch failure (all 
with stoma) 
 10 -2.6 (9.0)  0.51 
Any late 
complications 
 65 -1.3 (9.6)  0.59 
Average TOTAL 
Costs in NZD (year 
2013) 
     
<$300  32 2.5 (8.2) (Reference)  





Costs in NZD (year 
2013) 
     
<$300  57 -0.8 (9.4) (Reference)  
>$300  27 -1.3 (11.2) -0.5 (-5.6 to 4.7) 0.83 
Average Indirect 
Costs in NZD (year 
2013)  
     
<$300  40 2.5 (9.1) (Reference)  
>$300  41 -4.5 (9.9) -7.0 (-10.3 to -1.9) 0.01* 
* = p value less than 0.05 
 
Eighty-four participants completed the IBD-DI questionnaire. The average IBD disability score 
for this study was -1.0, with the standard deviation of 9.9. Participants who were older than 
41 at the time of surgery had a lower score than those who were younger than 41. 
Participants whose position at work was affected by their bowel condition or took more than 
100 days of leave in the past 12 months, had a significantly lower IBD-DI score. Participants 
who had ulcerative colitis and those who did not have Crohn’s disease had a higher average 
score. In terms of surgical indications, participants who had an IPAA because they had FAP, 
for malignancy prophylaxis, had a higher average score than participants whose indication 
for surgery was failed medical therapy. Participants who had an average total costs or 
indirect costs greater than NZD$300, had a lower IBD-DI score than those with the average 
total costs and indirect costs less than NZD$300.  
 
3.8 Correlation between IBDQ and IBD-DI 
There was a significantly positive correlation between the IBDQ and the IBD-DI, with r = 0.84 






Figure 3.2- Scatterplot between IBDQ and IBD-DI 
 
3.9 Comparison with Sydney cohort 
 
The IBD-DI and IBDQ results for UC patients in this study was compared to a cohort of 41 
medically treated UC patients from a Sydney study by Leong et al. The Sydney study used the 
same two questionnaires, and was being carried out simultaneously. The raw de-identified 
data were provided by the Sydney study investigators for a direct comparison. The Sydney 
study had the following median scores for IBD-DI: -5 for UC and +10 for controls; they found 
a score of +2.5 or more distinguished controls from disease groups. 
 
Table 3.11 - Comparison of Canterbury cohort versus Sydney cohort 
 
The mean IBD-DI score was -0.49 for IPAA patients in Canterbury, compared with -6.39 for 
medically treated UC patients in Sydney, with the p-value of 0.04, which is statistically 
significant. These results show that IPAA patients in Canterbury experiences less disability 




t(df) p value 
IBD-DI -0.49 -6.39 t[53.63] = 2.10 0.04 




than medically treated UC patients in Sydney.  The average IBDQ score was 172.9 for IPAA 
patients in Canterbury, compared with 159.4 for medically treated UC patients in Sydney, 
with the p-value of 0.09, which shows the difference in quality of life is not statistically 
significant between the two groups.  
 
3.10 Work disability and education 
Table 3.12 - Participant work disability and education 
Participant characteristics and work disability Frequency (Percentage)  
Level of education obtained     
Did not complete Secondary School 
Completed Secondary School as their highest level of 
education 
Completed Tertiary Education or trades/apprenticeship 
Declined to answer 








Education affected by bowel condition/IPAA 
Yes 
No 
Declined to answer 









Never been employed 
Declined to answer 







Position at work affected by bowel condition/IPAA 
Yes 
No 
Declined to answer 










Not at all 
Slightly 
Moderately 
Quite a bit 
Extremely 
Declined to answer 








Number of days of leave taken in the last 12 months 21.7 (62.3) 




Combination of leave 
Did not require leave 








Job lost as a result of bowel condition/IPAA 
Yes 
No 







Education – 49% of participants completed secondary education, 31% completed tertiary 
education, and 7% completed trade apprenticeship as their highest level of education 
obtained. 85% stated that their level of education was not affected by their bowel condition, 
and 10% believed that it was affected by their bowel condition. 
 
Employment – 67% of participants were currently employed, 25% were previously 
employed, and 3% of participants had never been employed. 
 
Position at work – 73% of participants believed that their position at work was not affected 





Work productivity - Participants were asked if their work productivity was affected by their 
IPAA: 42% said that their work productivity was not at all affected, 24% said that it was 
slightly affected, 8% said it was moderately affected, 10% said it was affected quite a bit, and 
7% said it was extremely affected. 
Leave taken – The majority of participants only required 0-5 days of leave over the last 12 
months. In contrast, a few participants lost their job as a result of their bowel 
condition/IPAA, and therefore took the maximum of 255 days of leave off work. 
 
58% of participants had not taken any leave in the last 12 months due to their IPAA/bowel 
condition. For those who required leave as a result of their IPAA: 12.5% took sick leave, 1% 
took annual leave, 12.5% took unpaid leave, and 12.5% took a mixture of leave that was 
available. 
 
Job loss – 6% of participants lost their jobs after IPAA surgery, as they were forced to take a 
prolonged amount of time off work in order to recover. Some needed to take six months off 
work, some could only work part time intermittently, and one particular participant found it 









3.11 Direct costs 
 
Direct costs included the costs of surgical procedures including and not limited to: IPAA 
surgery, other surgical procedures associated with IPAA, and day procedures; costs of 
inpatient admission which includes: emergency department visits, laboratory tests, 
radiography, and pharmaceuticals; as well as costs of outpatient contact which includes: 
outpatient clinic visits, general practitioner visits, prescriptive medications, district nurse 
visits, and social worker visits. The data of annual direct costs were available from 2006/07 
financial year to 2012/13 financial year.  
 





Average direct costs 
(NZD) per year  
Mean (SD) 
Univariable analysis 
Difference (NZD) - Mean 




































Mean square between 
groups = 
1531196.54 
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Years since surgery 
Less than 12 


















Less than 41 






-677.91 (-1846.92 to 941.10) 
 
0.252 
















Mean square between 
groups = 
4569633.21 





































































Mean square between 
groups = 
5867711.66 




























Mean square between 
groups = 
12808355.14 
F = 1.783 
 
0.140 





































914.78 (-987.87 to 2817.44) 
-766.66 (-2901.96 to 
1368.63) 
-492.51 (-2505.71 to 
1520.70) 
754.22 (-1743.47 to 
3251.91) 












































538.48 (-623.20 to 1700.16) 
225.18 (-937.22 to 1387.58) 
1375.56 (256.43 to 2494.69) 
396.79 (-1280.27 to 
2073.86) 









































































-15.54 (-37.45 to 6.37) 
-13.34 (-38.48 to 11.81) 




IBD Disability Index 84 N/A -22.25 (-80.84 to 36.33) 0.452 
* = p value less than 0.05 
 
Participants who had surgery more than 12 years ago, had significantly lower direct costs 
than those who had surgery less than 12 years ago. Participants who had perianal disease as 
a late complication had higher direct costs compared to participants who did not have 
perianal disease. Those who had total costs and indirect costs greater than NZD$300 in the 
last 12 months, were associated with having significantly higher direct costs. 
 
3.12 Indirect costs 
 
Indirect costs of the past 12 months included: work or school absenteeism, loss of work 
productivity, use of alternative or complementary health resources, travel, carers, tutors and 
additional phone or internet requirements. 
 
Indirect costs that were incurred through work absenteeism as a result of illness were 
calculated by the human capital method as described by Drummond et al (125). In this 
method, participants were asked the number of days they had off work as either unpaid or 
annual leave related to IPAA, which were then transferred into hours off work and multiplied 
by their gross hourly wage. For participants who were unemployed, their indirect costs were 
discussed descriptively as monetary values. 
 
Table 3.14 - Indirect costs 
Indirect costs Mean (NZD) 
(SD) 
Minimum Maximum 





Cost of non-prescription medication in the last 
12 months 




Cost of alternative health resources in the last 
12 months 
131.06 (484.86) 0 3000.00 
Cost of other cost items in the last 12 months 214.16 (441.69) 0 2500.00 












costs (NZD) over 
last 12 months 
Mean (SD)  
Univariable analysis 
Difference (NZD) - Mean 
(95% CI) or Report 
estimate (95% CI) 
 
p value 





































Mean square between 
groups = 57215791.088 
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Less than 12 
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Mean square between 
groups = 54870039.347 





































Days of leave taken 









































Mean square between 
groups = 27670235.188 




































Mean square between 
groups = 63333278.769 











































-333.21 (-7619.35 to 
6952.93) 
-759.95 (-8497.00 to 
6977.11) 
5700.73 (-1936.12 to 
13337.58) 
18284.20 (9078.61 to 
27489.79) 


















































3669.62 (-552.52 to 
7891.76) 
-2316.93 (-6552.74 to 
1918.88) 



























3536.97 (-2487.83 to 
9561.76) 








































































-119.73(-194.35 to -45.11) 
-137.31(-221.39 to -53.23) 





IBD Disability Index 84 N/A -217.08(-421.98 to -12.19) 0.038* 
* = p value less than 0.05 
 
Participants’ indirect costs were significantly higher if their position was affected at work, or 
if they took more than 100 days off work in the past year due to their bowel condition. 
Participants who had pelvic sepsis(es) as an early complication, had higher indirect costs 
than those who did not have any early complications. Those who had total costs greater 
than NZD$300, were associated with higher indirect costs. Indirect costs in the past year had 








3.13 Total costs 
 
Total average cost is the average of the participants’ average direct costs and average 
indirect costs over the past 12 months.  
 





Average total costs (NZD) 
over last 12 months - Mean 
(SD)  
All participants 85 4790.26 (11328.56) 
 
The combined total average costs over the past 12 months for the 85 participants were 























Chapter 4. Discussion 
 
The Canterbury IPAA study is a population based cohort study of ileal pouch patients, with 
long term follow up of complications, functional outcomes, quality of life, disability and 
costs. This study provided the much needed New Zealand data on IPAA, which enabled 
comparisons to be made with international data. Findings on each of these outcomes and 




Surgical complications are often split into early and late complications. In the Canterbury 
IPAA cohort, 21% had an early complication. Of those who had an early complication, 8.6% 
had haemorrhage requiring transfusion, 8.6% had a wound infection, 7.4% had pelvic sepsis, 
and 4.9% had small bowel obstruction. The majority (79.0%) of the study participants did not 
have any early complications.  
 
The early complication rate observed in the Canterbury IPAA populations compared 
favourably to a 2017 Canadian study involving 758 IPAA patients. In this Canadian study, the 
rate of wound infection was 14.3%, pelvic sepsis 17.8%, and small bowel obstruction 14.3%; 
the early complication rate observed in this study was much higher than the Canterbury 
study (42). In a 2016 systematic review, the average early complication rate was 21%, pelvic 
sepsis 3%, and small bowel obstruction 8% (2). The Canterbury early complication rate was 
comparable to this systematic review, except for the slightly higher rate of pelvic sepsis. 
Overall, Canterbury IPAA early complication rate is comparable to international data, and 
featured more favourably in certain domains.  
 
The late complication rate observed in the Canterbury IPAA study was 74.1%, with the 
following breakdown:  pouch failure 12.7%, strictures 16.0%, abscess or fistula 27.2%, small 
bowel obstruction 40.7%, pouchitis 58.2%. The late complication rate in the Canterbury IPAA 
study was much higher than what was reported in the international data. A large systematic 
review showed overall late complication rate ranged between 17%-55% (2). The same 




6%, small bowel obstruction 17%, pouchitis 29%. The Canterbury IPAA study had much 
higher rates in each of these late complications compared to this systematic review. Another 
study reported late complication rates of strictures to be 7.3%, and fistulas 3.4% (42), which 
were both lower than rates seen in the Canterbury IPAA study. Overall, The Canterbury IPAA 
study had a far higher late complication rate than international current literature.  
 
There are many reasons that could explain the difference of complication rates found 
between international studies.  Firstly, studies often have different definitions of major 
complications. This could lead to a large difference between complication rates. Secondly, 
the methods of data collection and analysis vary widely between international studies, and 
this would affect the complication rate.  
 
One of the reasons that could attribute to the higher late complication rate of the 
Canterbury IPAA study, is that data on long term outcomes and complications of participants 
were determined by assessing not only the hospital records, but also records from general 
practices. The most common IPAA complication is pouchitis; when patients have a flare of 
pouchitis, they are likely to present to their GP first. Pouchitis often settles with a course of 
antibiotics, which is often prescribed by the GP, thus these patients would not need to 
present to the hospital system. The majority of international studies did not include data 
from general practice. Therefore, the true rate of pouchitis and other late complications 
might be significantly underestimated in international data.  
 
Another possible explanation which may add to the higher complication rate is the long 
follow up period and cumulative effect of late complications. One of the participants in the 
Canterbury study had his IPAA made in the 1980’s, which meant he had the retrospective 
follow up of approximately 35 years. Through international research, it is known that the risk 
of developing pouchitis increases over a lifetime, with 40% patients reporting at least one 
episode over 10 years of follow up, to 70% of patients reporting at least one episode over 20 
years of follow up (45). The cumulative effect was evident in another study, which showed 
the pouch failure rate to be 4%, 6%, and 6% after 5, 10, and 20 years respectively (45).  
 
Therefore, both the cumulative effect as well as more complete data collection which 




IPAA study. In conclusion, there is a need for large international studies with long follow up 
periods, standardised international complication definitions, as well as inclusion of GP data 
in data collection, for a more accurate indication and comparison of complication rates.  
 
4.2 Functional outcomes 
 
In the Canterbury IPAA study, participants’ average number of bowel motion in 24 hours was 
7.24, and night time bowel motion was 1.63. This 24-hour bowel motion frequency is on the 
high end of the spectrum when compared to international data, with large systematic 
reviews reporting average stool frequency to be between 5-7 in 24 hours.  
 
This result of slightly higher bowel motion frequency could be explained by the long follow 
up period of the Canterbury study. It was observed that there is an increase of daytime and 
night time defaecation frequency, as well as nocturnal leakage and urgency (2, 43, 45, 47-49) 
with the passage of time. When the New Zealand data was compared to studies with long 
follow up periods, the bowel motion frequency per 24 hours is found to be comparable to 
international data.  
 
4.3 Quality of life 
 
Quality of life is an important outcome measure due to the young age of diagnosis of UC. 
The patients’ quality of life over their lifetime, including their productive years, is a vital 
consideration when making treatment decisions.  
 
In the Canterbury IPAA study, quality of life was measured by two different questionnaires: 
SF36 and IBDQ. The SF36 was split into several components; the results of these components 
from the Canterbury IPAA were comparable to international studies (4, 5, 8, 84, 95). Some of 
these studies compared its results to those of the general healthy population, and the 
conclusions were mixed – some found no difference in the SF36 score between IPAA group 
and the general population, whilst others found the general population had a higher SF36 
score than the IPAA group. In contrast, there were studies which had higher SF36 scores 
when compared with the Canterbury IPAA study (8, 83, 90, 98). However, one of these 




disease pathogenesis and symptom profile, in that they would be at a much lower risk of 
developing certain late complications, such as pouchitis. Therefore, one could expect the 
QoL of FAP patients to be higher than UC patients with an IPAA.  
 
When the IBDQ score of the Canterbury study was compared with international data, it 
appeared that most studies used the short version of the IBDQ score to evaluate QoL in the 
IPAA population. Therefore, the scores were not directly comparable. One small study did 
utilise the full IBDQ for its patient cohort, and when compared with the IBDQ score of the 
Canterbury IPAA study, this study had a lower IBDQ score. However, due to its small study 
size, the difference in the IBDQ score may not be of statistical significance.  
 
When it came to comparing quality of life of patients with an IPAA to those on medical 
therapy, research was certainly found to be lacking. The Canterbury IPAA study wanted to 
help bridge this gap by adding to the current research data available, and did so by 
comparing its IBDQ score to a cohort of medically treated UC patients in Sydney. The result 
of this comparison, was that there was no statistically significant difference of the IBDQ 
score between the Canterbury IPAA group and the Sydney medically treated group.  Two 
international studies which compared IPAA with medical treatment, had the same result 
conclusion as the Canterbury IPAA study (5, 98). Despite the importance in comparing scores 
of the IPAA group with the medical treatment group, this can be a very difficult task; due to 
the fact that the most common reason for elective IPAA surgery is disease resistant to 
medical therapy (25, 29, 53, 126). This fact alone indicates that the surgical group is likely to 
have higher disease severity compared to the medical treatment group. Therefore, 
comparison between the two groups can be likened to comparing apples with oranges. 
What is needed in future research to enable removal of any bias, is to measure the quality of 
life prior to surgery, and compare this to after surgery of the same patient cohort. This 
would give a true indication of whether there is a difference between the two groups.  
 
The Canterbury IPAA study found that across the three questionnaires, certain risk factors 
were found to increase the risk of a lower quality of life. These factors were: female, 
unemployment, position affected at work, taken >100 days of sick leave, Crohn’s disease, GI 
obstruction, pelvic sepsis, strictures, peri-anal disease, pouch failure, any late complications, 




result was echoed by international studies, which also found that pelvic sepsis, poor pouch 
function, medical co-morbidities and psychiatric illness increase the likelihood of a lower 
quality of life (4, 50, 93). However, there was no international research on whether gender, 
work disability, and costs were risk factors for a lower quality of life. Future research is 
needed in this area, in order to isolate risk factors which leads to a lower quality of life. This 
information would no doubt influence treatment decisions for patients.  
 
One of the short comings of the Canterbury IPAA study, is that the IBDQ and SF36 scores 
were not compared to scores of the normal population. This points to a need for future 
research to find the average IBDQ and SF36 scores in the healthy New Zealand population, 
to enable comparisons to be made to the Canterbury IPAA population, and therefore, 
comparisons to international data. 
 
It must be noted, that one of the problems encountered in the literature review was that the 
majority of studies used different methods to assess QoL. This made it very difficult to 
compare results directly. Two systematic reviews on the quality of life of IPAA had the same 
conclusion (86, 97). Future research in this area should focus on having an international 




Disability is an objective measure of the effects of disease, which many experts believe are 
becoming an increasingly important endpoint alongside quality of life, which is a subjective 
measure of the effects of disease. Peyrin-Biroulet et al developed the world’s first disability 
measurement tool that is specific to inflammatory bowel disease – the Inflammatory Bowel 
Disease Disability Index (100). The IBD-DI score ranges from -80 to +22; the more negative 
the score, the higher the level of disability. The IBD-DI was validated in 2014, concluding that 
IBD-DI was a valid tool for measuring disability, and was able to differentiate CD and UC from 
controls (medians -7, -4, +10; p value 0.001) with a score of >3.5 identifying controls with 
94% sensitivity and 83% specificity (104). One shortcoming of the IBD-DI is that it must be 
implemented via interview and has not yet been validated for self-report. However, a 
current study in the University of Otago which is working on validating the IBD-DI for self-





The IBD-DI addresses many of the functional issues faced by IPAA patients, including 
frequency of bowel motions, presence of blood in stools, interference with sleeping, 
abdominal pain and body image. These factors give it face validity as an appropriate tool to 
assess disability in IPAA patients in addition to IBD patients who have not undergone 
colectomy. The IBDQ and IBD-DI have a number of similar constructs and hence the strong 
but imperfect correlation. This imperfect correlation and the varying associations found in 
the present study suggest the two scores are unique but overlapping.  
 
The advantage of an objective measure such as the IBD-DI, is that it provides specific 
information regarding the presence and frequency of multiple functional outcomes. The 
disadvantage of an objective measure, is that it may not capture how these functional 
outcomes affect patients at a personal level. The advantage of a subjective measure, is that 
it captures how the patient feels about their physical function and how it affects them 
personally. The disadvantage is of a subjective measure, is that the results are dependent on 
the specific study population, and may vary widely. For the same complication or functional 
outcome, patients may feel and be affected very differently.   
 
This study was the first to apply the IBD-DI to a well-characterised population-based cohort 
of restorative proctocolectomy with IPAA patients with long term follow up. Due to the 
recent development and validation of the IBD-DI, at the initiation of the Canterbury IPAA 
study in 2013, there were no other studies which had used the IBD-DI in patients with an 
IPAA. Between 2013 and the conclusion of this thesis at the end of 2017, two new studies 
had used IBD-DI to evaluate disability in IBD and IPAA patients.   
 
The first study which used the IBD-DI was an Australian study which validated the use of the 
IBD-DI. Results from this study found the median score to be -7 and -4 for CD and UC 
patients respectively; both of these scores were lower than the average IBD-DI score of -1 
from the Canterbury IPAA study (104). The second study was a Belgium study which included 
59 IPAA patients. It had a much higher average IBD-DI score of 17.9 (8.9-28.6) than the 
average score of -1.0 in the Canterbury IPAA study (90). Since the IBD-DI had the maximal 
score of +22, with the score of >3.5 identifying as controls/healthy population without IBD, it 




comparison is unlikely to be valid due to uncertainty of whether the IBD-DI was scored 
correctly in this Belgium study.  
 
The IBD-DI results for UC patients who had an IPAA in the Canterbury IPAA study was 
compared to a cohort of 41 UC patients from a Sydney study (104), which was being carried 
out simultaneously. The results were that the IBD-DI score of the UC patients in the 
Canterbury IPAA study was higher (-0.49) than the average mean score from the Sydney 
cohort of medically treated UC patients (-6.39) with the p value of 0.04 (104). Results 
suggest that IPAA patients may have lower levels of disability than their medically treated 
counterparts. However, this comparison involves two very different groups of patients, as 
they were not matched for any important characteristics such as age, gender, length of time 
of medical treatment, and disease severity. Because one of the main indications for elective 
surgery is failed medical therapy, one could argue that IPAA patients may have had worse 
disease severity than patients’ whose disease is able to be controlled by medical therapy. 
Therefore, this conclusion cannot be generalised without further research from matched, 
large, multi-centre studies.  
 
Certain risk factors for higher level of disability (lower IBD-DI score) were identified in the 
Canterbury IPAA study: participants older than 41 at the time of surgery, position at work 
affected by bowel condition, took >100 days of leave, patients with CD, average total cost 
>NZD$300 and indirect cost >NZD$300. On the other hand, those patients who had an IPAA 
for the indication of FAP or malignancy prophylaxis, had a lower level of disability (higher 
IBD-DI score) than those who proceeded for IPAA for failed medical therapy. Of the few 
international studies on this topic, they did not find any disease-specific variables which had 
a statistically significant effect on the level of disability (5, 90).  
 
Disability can also include work disability, affecting work productivity, position at work, work 
absenteeism/sick leave, and loss of work. International studies point towards higher level of 
work disability in patients with IBD, compared to other disease groups and the general 
population (16, 101, 105-107, 109, 110). Due to the young age of onset of IBD, the increased 
level of work disability has a significant effect on this population. In addition, some studies 
point towards certain factors which increases the risk of work disability. One study found 




level of work disability (18). Another study found that patients with CD has a higher rate of 
unemployment, sick leave and disability than UC patients (105).  
 
In the Canterbury IPAA study, 18% believe their position at work was affected by their bowel 
condition, 49% state that their work productivity was affected by their bowel condition, 
average number of days of leave was 21.7 days, and 6% of participants lost their jobs after 
IPAA surgery, as they were forced to take a prolonged amount of time off work in order to 
recover. There were limited international studies on the topic of IPAA and work disability for 
comparison of results. One study of 64 IPAA patients found that 5% received disability 
pensions and 9% had reduced workloads (46). The percentage of those who had lost their 
jobs as a result of work disability was comparable between this historic study and the 
Canterbury IPAA study. Another study compared absenteeism, presenteeism and work 
productivity of IPAA group versus medical treatment group, and found there was no 
significant differences between the two groups (5).  
 
In conclusion, there are very few studies on the topic of IPAA and disability, and work 
disability. Disability as an objective measure of outcome adds important information 
regarding physical function that a subjective measure does not provide. However, it is also 
important to ascertain the subjective measure to provide information on the personal 
impact it has on patients. More research is required in order for comparisons to be made to 




Cost and cost-effectiveness of IBD treatments is an important outcome measure due to the 
early age of onset of disease, which makes for a long period of lifetime costs and large 
economic societal burden. In Europe, an estimated 2.5-3 million people are affected by IBD, 
with a direct healthcare cost of 4.6-5.6 billion Euros per year (101). The costs of treatments 
of IBD has increased since the introduction of biologics (98, 117, 127-129). Therefore, it is 
important to collect information and to compare the costs and cost-effectiveness of 





In the Canterbury IPAA study, the average total cost in 12 months was NZD$4,790.26, with 
the standard deviation (SD) of NZD$11,328.56. This was further broken down into the 
average direct cost of NZD$930.42 (SD NZD$3,144.87) and average indirect cost of the past 
12 months of NZD$3,825.38 (SD NZD$9,930.00). Indirect costs included costs resulting from 
work absenteeism and job loss; the highest indirect costs in this study was NZD$50,500.00. 
When compared with international studies, the direct costs were much lower than what was 
reported in various studies (80, 98, 116, 119). It has been shown in certain studies that after 
the high initial costs of the three-stage surgery, the costs reduce dramatically over time, 
which is associated with long term economic benefits (116).  
 
There are several large international studies which compared cost and cost-effectiveness of 
surgery to medical therapy, and the majority of these studies concluded that surgery was 
more cost-effective, particularly in the long run (80, 98, 111, 116, 117, 119, 129). A Markov 
model by Park et al showed that the lifetime costs of standard medical care was higher 
compared to early colectomy with IPAA, as well as more QALY gained for IPAA group (80). 
Another study found that IPAA had lower costs, and did not increase risk of disability in 
patients with severe UC, and concluded that “the value of prolonged medical therapy in this 
select group of patients is questionable” (111). However, it must be noted that this was a 
small study, with only 20 patients in each of the surgical and medical group.   
 
Certain risk factors were identified in the Canterbury IPAA study with higher costs: pelvic 
sepsis, perianal disease, taken >100 days off work in the past year due to their bowel 
condition. The study also found that higher indirect costs were associated with having higher 
direct costs, and vice versa. Other studies concurred with these results, particularly that of 
complications such as pelvic sepsis and pouchitis increased the risk of higher costs (116, 119, 
130, 131).  
 
For indirect costs, the Canterbury IPAA study showed the average indirect costs were 
comparable to international data. The average indirect costs per year (from work 
absenteeism) ranged from CAD$868 to €6821 in different studies (16, 110, 120). However, it 
must be noted that due to the lack of standardised definition, inclusion of what indirect 
costs entails, and method of data collection, a direct comparison between international 




on IPAA and indirect costs based on absenteeism, presenteeism and loss of leisure (110). 
Despite the difficulty in measuring indirect costs, it is a cost that should not be 
underestimated. In the Canterbury IPAA study, average indirect costs accounted for 79.9% of 
average total costs. This percentage was much higher than what was reported in 
international studies, which showed indirect costs to be roughly one-third of all costs (110, 
121).  
 
The Canterbury IPAA study may have a higher proportion of indirect costs due to the 
extensive method of data collection, which included asking participants to fill out an indirect 
cost questionnaire, including costs such as work or school absenteeism, loss of work 
productivity, costs of alternative or complementary treatments, travel costs, carers, tutors, 
and phone and internet requirements. Other studies focused on costs associated with work 
absenteeism, and did not include other components as above.  
 
Another reason for the high indirect costs could be the fact that indirect costs that were 
incurred through work absenteeism as a result of illness, were calculated by the human 
capital method as described by Drummond et al (125). In this method, for those few 
participants who lost their jobs as a result of their bowel condition, it would calculate the 12 
months’ worth of lost income. The highest recorded indirect cost was NZD$50,500; this 
figure would significantly increase the average indirect cost across the study. Therefore, the 
average may not be an accurate reflection of the true average indirect cost for participants. 
Indirect costs are an important issue that requires further research, in particular, a 
requirement for a standardised definition and method of measuring indirect costs to be used 
internationally.  
 
In conclusion, there are limited international studies on the direct and indirect costs 
associated with IPAA. The comparisons between these few studies were made difficult by 
the lack of standardised method of data collection and analysis. It is apparent that more 
research is needed in this area, in particular development of an international standardised 







4.6 Study limitations 
 
There were a number of limitations for this study. Many of the eligible people were unable 
to be contacted. Out of the 136 IPAAs performed in Christchurch since 1984, 29 (21.3%) 
were uncontactable. Nevertheless, the response rate among contactable and eligible people 
was high (88.5%). The final number of participants who completed all the questionnaires in 
this population study was 80. This is a small study number, which is a reflection of the small 
size of this region and country in comparison to large cities in Europe or USA. This was a 




Current literature reveals insufficient research on IPAA and disability, and direct and indirect 
costs. There remain unanswered questions when it comes to comparing results of IPAA with 
medical treatment for various outcomes, such as quality of life and disability. The Canterbury 
IPAA study provided novel findings from population cohort data on complications, functional 
outcomes, quality of life, disability, direct and indirect costs. This study was the first to use 
the IBD-DI in an IPAA population, and showed excellent correlation between the IBDQ and 
the IBD-DI. The information gathered from this study enabled comparisons to be made to 
international studies, which showed similarities in the level of quality of life and disability. 
The study found that with comprehensive, long term follow up, the late complication rate 
was higher than what was reported in other studies, which likely underestimated the true 
rate of late complications. Lower QoL and disability were found in those who had their 
position affected at work and those who had more than 100 days off work in the last year. 
Lower QoL and disability scores were associated with perioperative complications and higher 
indirect and total costs (p <0.01). This study was the first to use the IBD-DI to compare 
medically treated UC patients with those who had an IPAA, and found that patients with an 
IPAA had less disability than medically treated UC patients (p = 0.04). Ultimately, all of the 
specific and novel information from this study will be important for patients, clinicians and 
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The Inflammatory Bowel Disease Questionnaire 
 
The following questions ask about your bowel problem and how it affected your life over the 
last two weeks. Please tick one answer for each of the questions. If you are unsure about 
how to answer any question, just give the best answer you can. Do not spend too much time 
answering, as your first thoughts are likely to be the most accurate. 
 
1. On how many days over the last two weeks have you had loose or runny bowel 
movements? 
1.1. none 
1.2. on one or two days only 
1.3. on three to seven days 
1.4. on eight to fourteen days (ie more than every other day) 
 
2. On how many days over the last two weeks have you felt tired? 
2.1. none 
2.2. on one or two days only 
2.3. on three to seven days 
2.4. on eight to fourteen days (ie more than every other day) 
 
3. In the last two weeks have you felt frustrated? 
3.1. No, not at all 
3.2. Yes, some of the time 
3.3. Yes, most of the time 
3.4. Yes, all of the time 
 
4. In the last two weeks, has your bowel condition prevented you from carrying out your 
work or other normal activities? 
4.1. No, not at all 
4.2. Yes, for one or two days 
4.3. Yes, for three to seven days 





5. On how many days over the last two weeks have you opened your bowels more than 
three times a day? 
5.1. none 
5.2. on one or two days only 
5.3. on three to seven days 
5.4. on eight to fourteen days (ie more than every other day) 
 
6. On how many days over the last two weeks have you felt full of energy? 
6.1. none 
6.2. on one to two days only 
6.3. on three to seven days 
6.4. on eight to fourteen days (ie more than every other day) 
 
7. In the last two weeks have you been worried about being admitted to hospital because 
of your bowel problem? 
7.1. No, not at all 
7.2. Yes, some of the time 
7.3. Yes, most of the time 
7.4. Yes, all of the time 
 
8. In the last two weeks did your bowel condition prevent you from going out socially? 
8.1. No, not at all 
8.2. Yes, some of the time 
8.3. Yes, most of the time 
8.4. Yes, all the time 
8.5. does not apply to me 
 
9. On how many days over the last two weeks have your bowels opened accidentally? 
9.1. none 
9.2. on one or two days only 
9.3. on three to seven days 





10. On how many days over the last two weeks have you felt generally unwell? 
10.1. none 
10.2. on one or two days only 
10.3. on three to seven days 
10.4. on eight to fourteen days (ie more than every other day) 
 
11. In the last two weeks have you felt the need to keep close to a toilet? 
11.1. No, not at all 
11.2. Yes, some of the time 
11.3. Yes, most of the time 
11.4. Yes, all of the time 
 
12. In the last two weeks, has your bowel condition affected your leisure or sports 
activities? 
12.1. No, not at all 
12.2. Yes, some of the time 
12.3. Yes, most of the time 
12.4. Yes, all of the time 
12.5. does not apply to me 
 
13. On how many days over the last two weeks have you felt pain in your abdomen? 
13.1. none 
13.2. on one or two days only 
13.3. on three to seven days 
13.4. on eight to fourteen days (ie more than every other day) 
 
14. On how many nights over the last two weeks have you been unable to sleep well (days 
if you are a shift worker)? 
14.1. none 
14.2. on one or two nights only 
14.3. on three to seven nights 





15. In the last two weeks have you felt depressed? 
15.1. No, not at all 
15.2. Yes, some of the time 
15.3. Yes, most of the time 
15.4. Yes, all of the time 
 
16. In the last two weeks have you had to avoid attending events where there was no 
toilet close at hand? 
16.1. No, not at all 
16.2. Yes, some of the time 
16.3. Yes, most of the time 
16.4. Yes, all of the time 
 
17. On how many days over the last two weeks, have you had a problem with large 
amounts of wind? 
17.1. none 
17.2. on one or two days only 
17.3. on three to seven days 
17.4. on eight to fourteen days (ie more than every other day) 
 
18. On how many days over the last two weeks have you felt off your food? 
18.1. none 
18.2. on one or two days only 
18.3. on three to seven days 
18.4. on eight to fourteen days (ie more than every other day) 
 
19. Many patients with bowel problems have worries about their illness. How often during 
the last two weeks have you felt worried? 
19.1. No, not at all 
19.2. Yes, some of the time 
19.3. Yes, most of the time 





20. On how many days over the last two weeks has your abdomen felt bloated? 
20.1. none 
20.2. on one or two days only 
20.3. on three to seven days 
20.4. on eight to fourteen days (ie more than every other day) 
 
21. In the last two weeks have you felt relaxed? 
21.1. No, not at all 
21.2. Yes, some of the time 
21.3. Yes, most of the time 
21.4. Yes, all of the time 
 
22. On how many days over the last two weeks have you noticed blood with your bowel 
movements? 
22.1. none 
22.2. on one or two days only 
22.3. on three to seven days 
22.4. on eight to fourteen days (ie more than every other day) 
 
23. In the last two weeks have you been embarrassed by your bowel problem? 
23.1. No, not at all 
23.2. Yes, some of the time 
23.3. Yes, most of the time 
23.4. Yes, all of the time 
 
24. On how many days over the last two weeks have you wanted to go back to the toilet 
immediately after you thought you had emptied your bowels? 
24.1. none 
24.2. on one or two days only 
24.3. on three to seven days 
24.4. on eight to fourteen days (ie more than every other day) 
 




25.1. No, not at all 
25.2. Yes, some of the time 
25.3. Yes, most of the time 
25.4. Yes, all of the time 
 
26. On how many days over the last two weeks have you had to rush to the toilet? 
26.1. none 
26.2. on one or two days only 
26.3. on three to seven days 
26.4. on eight to fourteen days (ie more than every other day) 
 
27. In the last two weeks have you felt angry as a result of your bowel problem? 
27.1. No, not at all 
27.2. Yes, some of the time 
27.3. Yes, most of the time 
27.4. Yes, all of the time 
 
28. In the last two weeks, has your sex life been affected by your bowel problem? 
28.1. No, not at all 
28.2. Yes, some of the time 
28.3. Yes, most of the time 
28.4. Yes, all of the time 
28.5. does not apply to me 
 
29. On how many days over the last two weeks have you felt sick? 
29.1. none 
29.2. on one or two days only 
29.3. on three to seven days 
29.4. on eight to fourteen days (ie more than every other day) 
 
30. In the last two weeks have you felt irritable? 
30.1. No, not at all 




30.3. Yes, most of the time 
30.4. Yes, all of the time 
 
31. In the last two weeks have you felt lack of sympathy from others? 
31.1. No, not at all 
31.2. Yes, some of the time 
31.3. Yes, most of the time 
31.4. Yes, all of the time 
 
32. In the last two weeks have you felt happy? 
32.1. No, not at all 
32.2. Yes, some of the time 
32.3. Yes, most of the time 































Indirect cost Questionnaire 
 
Instructions for this questionnaire: Please answer every question. Some questions may look 
like others, but each one is different. Please take the time to read and answer each question 
carefully by selecting the answer that best represents your response. 
 
What is your Study ID? (This was given to you in an email or a letter; if you have lost your 







1.   What is the highest level of education you have obtained? 
1. Secondary education 
2. Tertiary education 
3. Decline to answer 
4. Other _______________________________________________________ 
 
2.   Do you feel your level of education obtained was affected by your ileal pouch?  
1. Yes 
2. No 
3. Decline to answer 
 
3.    Are you currently employed?  
1. Yes 
2. No 
3. Decline to answer 
 
4.   Were you previously employed? 









Note: If you are not currently employed, but were previous been employed, please answer 
the following questions in relation to your previous work. 
 
5. How many hours do you work in a typical work day? (If you do not wish to answer this 















7. Have you had to have time off work in the last 12 months due to your ileal pouch? 
1. Yes 
2. No 
3. Decline to answer 
 
7a. How many days have you had off work in the last 12 months due to your pouch? (If you 










7b. These days were taken off work as: 
1. Unpaid leave 
2. Annual leave 
3. Sick leave 
4. Decline to answer 
5. Other  
 




3. Decline to answer 
 
9. Has your ileal pouch affected your work productivity? 
1. Not at all 
2. Slightly 
3. Moderately 
4. Quite a bit 
5. Extremely 
6. Decline to answer 
 
10. Have you used non-prescription medication for your pouch in the last 12 months? 
1. Yes 
2. No 
3. Decline to answer 
 
10a. What was the cost of your non-prescription medication over the last 12 months? (If you 














3. Decline to answer 
 
11a. What was the cost of your alternative health therapy over the last 12 months? (If you 







12. Can you think of any other costs that have arisen due to your ileal pouch? For example: 
travel, carer, tutor, cleaner, additional phone or internet requirements.  
1. Yes 
2. No 
3. Decline to answer 
 
12a. What was the item(s)/resource(s) that added to the cost of your ileal pouch? (If you do 










12b. What was the cost of this item(s)/resource(s) over the last 12 months? (If you do not 
wish to answer this question, enter Decline to answer) 
 
 
 
 
 
 
